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ABSTRACT 
Asthma is an inflammatory disease of the airways characterised by airway 
remodelling and hyperresponsiveness.  New treatments are needed for patients 
with severe asthma whose disease is not controlled with currently available 
therapies.  Asthma pathophysiology is complex, however, accumulating 
evidence suggests multiple inflammatory pathways in asthma converge onto a 
relatively small number of downstream targets that may be of therapeutic 
interest.  These include mitogen activated protein kinases (MAPKs), the pro-
inflammatory transcription factors nuclear factor-κB (NF-κB) and activator 
protein-1 (AP-1) and transcriptional regulators such as histone acetyl 
transferases (HATs) and histone deacetylases (HDACs).  Chemokines are 
molecules secreted at sties of inflammation, attracting inflammatory cells and 
perpetuating the inflammatory response.  Here we studied the mechanisms by 
which the pro-inflammatory mediator endothelin-1 (ET-1) and the cytokine 
tumour necrosis factor-α (TNF-α) promoted expression by primary human 
airway smooth muscle cells (HASMC) of two important chemokines, 
monocyte chemotactic protein-1 (MCP-1) and eotaxin.  Further, we studied the 
mechanisms by which existing asthma therapies (long acting beta agonists 
(LABA) and glucocorticoids) modulated TNF-α-stimulated eotaxin expression.  
Endothelin-1 stimulated MCP-1 release through a transcriptional mechanism 
involving NF-κB and AP-1; the upstream signalling pathway involved p38 and 
p44/p42 MAPKs.  Previously, this lab showed that TNF-α-induced eotaxin 
release is also NF-κB-dependent, involving histone H4 acetylation at the 
eotaxin promoter.  Here we found that TNF-α-induced eotaxin release does not 
involve histone H3 acetylation, and that TNF-α-dependent histone H4 
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acetylation does not occur through alterations in total HDAC activity or levels 
of the key HDACs -1 and -2.  Similarly, modulation of TNF-α effects on 
eotaxin expression by glucocorticoids and LABA is independent of total 
HDAC activity and HDAC-1 and -2 levels.  These studies support the body of 
evidence suggesting that multiple inflammatory pathways in asthma converge 
onto a small number of downstream targets, and are relevant to the 
understanding and treatment of asthma. 
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CHAPTER 1:  INTRODUCTION 
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1.1  Asthma 
Asthma is an inflammatory disease of the airways characterised by airway 
hyperresponsiveness (AHR) and airway remodelling.  AHR leads to variable 
airflow obstruction, manifest clinically by symptoms such as cough, wheezing, 
breathlessness and chest tightness.  The disorder can range in severity through 
a continuum from mild and intermittent to persistent and severe asthma that 
may be life-threatening.  Typically, inhaled spasmogens trigger an early 
asthmatic response characterised by bronchoconstriction, oedema of the airway 
wall and increased mucus secretion, which typically resolves within 2 to 3 
hours.  This is often followed by a late asthmatic response characterised by a 
longer period of bronchospasm, maximal between 6 and 12 hours and 
associated with an influx of inflammatory cells in the airways. 
 
Asthma affects around 5.2 million adults in the UK, and its prevalence is 
increasing (1).  It costs the NHS £889 million and the UK economy a total of 
£2.3 billion per annum.  Over 1400 people died from asthma in the UK in 2002 
(1).  The causes for asthma remain obscure but it is known that both genetic 
and environmental influences play a part.  At the airway level, the clinical 
syndrome of asthma is brought about by a complex interplay between a 
network of multiple inflammatory and structural airway cells.  These cells 
produce a vast array of biologically active molecules, including cytokines, 
chemokines, mediators, angiogenic factors, growth factors and matrix 
modifying enzymes, that act in an autocrine and paracrine manner to initiate 
and perpetuate airway inflammation and remodelling. 
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1.2  The immune response in asthma 
Airway inflammation is fundamental to the pathogenesis of asthma.  The initial 
trigger to this cascade of inflammatory responses is sensitisation to inhaled 
allergen.  Allergen is taken up and processed by antigen presenting dendritic 
cells residing under the airway epithelium, via IgE bound to high affinity cell 
surface receptors.  Following engagement with antigen, dendritic cells migrate 
to local lymphoid tissue.  There, they present processed antigen, loaded onto 
MHC class II HLA molecules, to naïve T cells residing within the lymphoid 
follicle.  This results in activation of the T-cell specific to that antigen, through 
co-stimulatory signals mediated by the interaction of CD28 on the surface of 
the T cell with CD80 (HLA B 7.1) or CD86 (B7.2) on the antigen presenting 
cell (APC) (2, 3).  The activated T-cell subsequently expresses IL-2 receptors, 
and proliferation (clonal expansion) is triggered by release of IL-2 from the 
APC (4).  Activated T-cells migrate back to the asthmatic airway under the 
influence of chemokines (5). 
 
Activation of T cells by antigen leads to their maturation into one of several 
different functional subsets, described below, dependent on their cluster 
differentiation (CD) marker status, and the inflammatory milieu.  CD4+ cells 
have the capacity to differentiate into T helper 1 (Th1), T helper 2 (Th2), 
regulatory T cells (Treg) or Th17 cells.  CD8+ cells develop into cytotoxic T 
cells (Tc).  The level of IL-12 secretion by dendritic cells affects the balance of 
Th1 versus Th2 responses, IL-12 shifting the balance towards the Th1 response 
(6).  Asthma is characterised by a predominantly Th2 phenotype (7).   
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Th2 cells are characterised by the production of IL-4, IL-5 and IL-13, and the 
presence of CCR4 and CCR8 receptors on their cell surface (4, 8).  Their 
physiological role is to protect against extracellular parasites through 
interaction with, and stimulation of antibody production by, B cells.  Human 
and animal studies support the concept of a Th2 dominant response in 
asthmatic airway inflammation.  Th2 cytokines are elevated in asthmatic 
patients at baseline and after subsegmental allergen challenge ((8) and 
references therein).  The Th2 cytokine IL-13 is overexpressed in patients with 
asthma (9, 10) and, furthermore, its expression is related to the degree of 
eosinophilic inflammation (11).  In murine models of asthma, IL-13 was both 
necessary and sufficient to cause airway hyperresponsiveness (AHR) (12), and 
depletion of CD4+ lymphocytes abolished AHR (13). 
 
B lymphocytes, like T-cells, express surface receptors specific for a particular 
antigen.  When a B-cell encounters its specific antigen, it internalises, 
processes and presents it to activated Th2 cells.  Again, in association with 
specific co-stimulatory signals (ie CD40 ligand on the T-cell surface and CD40 
on the B cell), IL-2 stimulation promotes clonal expansion of the B-cell.  The 
B-cell then differentiates into a plasma cell and secretes large amounts of 
soluble antibody corresponding to its specific surface receptor.  IL-4 and IL-13, 
secreted by Th2 cells, promote isotype switching of the B-cell to release IgE 
(4), which can then bind to high affinity receptors on the surfaces of mast cells.  
Subsequent exposure to the relevant inhaled allergen cross links the IgE on the 
mast cell surface, causing degranulation and activation of asthmatic airway 
inflammation. 
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1.3  Role of other immune cells in asthma 
1.3.1  T helper 1 cells 
Th1 cells are defined by the secretion of interferon γ (IFNγ) and tumour 
necrosis factor β (TNF β) (4).  Their role in asthma is unclear, with conflicting 
evidence as to whether they augment or attenuate asthmatic airway 
inflammation.  For example, some studies found that levels of INFγ and TNFα 
were elevated in the bronchoalveolar lavage fluid (BALF) of patients with 
asthma (14) and correlated with disease severity (15) suggesting that Th1 cells 
may contribute to the asthma phenotype and may be associated with more 
severe disease.  In support of this hypothesis, adoptive transfer of Th1 cells in 
one mouse model of asthma caused severe airway inflammation.  In contrast, 
however, similar experiments in different animal models demonstrated 
inhibition of airway inflammation and AHR by Th1 cells and IL-16 (which 
promotes differentiation of CD4+ cells towards a Th1 phenotype) (16-18).  In 
keeping with a potential negative regulatory effect of Th1 cells, Krug et al 
found a reduction in IFNγ-producing cells in asthmatic patients after segmental 
allergen challenge (19).  Perhaps most importantly, in asthmatic patients, 
inhaled IFNγ had no effect on symptoms, lung function or BALF eosinophil 
counts (20). 
 
1.3.2  Regulatory T cells 
Tregs are important regulators of autoimmunity.  They are naturally generated 
immune cells thought to be part of the host defence mechanism limiting the 
pathogen-triggered immune response, before it becomes overwhelming and 
 6 
causes excessive tissue damage.  Thus, it has been hypothesised that Treg 
recruitment into the asthmatic airway could suppress allergic inflammation.  In 
support of this hypothesis, Treg levels were reduced in BALF of children with 
asthma (21), normal patients had a higher frequency of peripheral blood Tregs 
compared to atopic patients, whereas atopic patients had higher peripheral 
blood levels of Th2 cells (22) and levels of Tregs were reduced in individuals 
with allergic rhinitis (23).  Furthermore, the Tregs of atopic patients were less 
able to suppress allergen-induced T-cell proliferation in vitro (23).  
Interestingly though, in another study, whilst Tregs were again found to be 
decreased in atopic versus non-atopic children, in the atopic group, the levels 
of Tregs were actually higher in those with more severe disease compared to 
those with mild disease.  Functional assays confirmed the competence of the 
Treg cells from this group (24).  The authors speculate that Tregs may be 
generated as a response to atopy and disease severity.  The concept that Tregs 
may downregulate allergic inflammation is supported by animal studies 
showing that adoptive transfer of Tregs into allergen sensitised mice prevented 
allergic airway inflammation and AHR (25, 26).  However, their role in asthma 
remains unclear. 
 
1.3.3  Th17 cells 
Little is known about the role of these recently described CD4+ T cells in 
asthma.  Th17 cells and their main product, IL-17, are important in 
inflammatory and autoimmune diseases (27).  IL-17 has been linked to 
neutrophilic lung inflammation and AHR in a mouse model (28), and release of 
neutrophil chemokines from airway epithelial cells in vitro (29).  IL-17 mRNA 
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levels were increased in the sputum of asthmatic patients, and correlated with 
sputum neutrophil numbers (30).  Th17 cells can also secrete IL-21, which 
inhibits Treg development (31) and IL-22, which has multiple actions on non-
immune cells in various organs, including the lungs (reviewed in (32)).  
However, more work is needed to fully understand the role of Th17 cells in 
asthma. 
 
1.3.4  Natural Killer T Cells 
Natural killer T (NKT) cells are a sub-population of T lymphocytes that 
function to recognise and kill virally infected cells and tumour cells.  Their role 
in asthma is controversial.  Akbari et al have proposed an important role for 
NKT cells in asthma based on their observations that these cells formed more 
than 60% of the CD4+ lymphocyte population in the BALF of patients with 
asthma (33) and that, in a mouse model, NKT cells were essential to the 
development of allergen induced AHR (34), a finding supported by others (35).  
However, others, who have criticised the methodology used by Akbari et al, 
showed the proportion of NKT cells in BALF of asthmatic patients to be less 
than 2.5% of the total lymphocyte population (36, 37) and, furthermore, these 
cells were not required for the development of allergic airway inflammation in 
a different mouse model (38).  The role of NKT cells in asthma remains 
uncertain. 
 
1.3.5  Cytotoxic T cells 
Like Th17 and NKT cells, there is uncertainty surrounding the role of CD8+ Tc 
cells in asthma.  Sputum CD8+
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release higher levels of IL-4, IL-5 and IFNγ compared to those from non-
asthmatic controls (39) suggesting a role for these cells in asthma pathogenesis.  
In a CD8+ deficient mouse model, ovalbumin-stimulated AHR and airway 
inflammation was significantly reduced, and adoptive transfer of CD8+ cells 
restored these responses (40).  In contrast, Das et al found that depletion of 
CD8+ cells had no effect on the development of allergic airway inflammation 
(38).  Several studies have found correlations between the number or activity 
of Tc cells and asthma severity (39, 41, 42) and viral asthma exacerbations, 
particularly fatal exacerbations (reviewed in (43)), suggesting these cells may 
assume more importance in severe disease.  However, their exact role remains 
unclear. 
 
1.3.6  Mast cells 
Mast cells are tissue cells housing numerous granules containing a host of pre-
formed mediators, including leukotrienes, histamine, tryptase and some 
cytokines.  They bear high affinity FCεRI IgE receptors on their surface.  
Crosslinking of these receptors, on binding of antigen-associated IgE, triggers  
mast cell activation and degranulation, with the release of both preformed and 
newly synthesised (PGD2, thromboxaneA2) mediators.  These mediators can 
both trigger bronchoconstriction and contribute, through their effects on other 
immune cells and airway structural cells, to ongoing airway inflammation.  As 
described in section 1.4.6.1, there is current interest in the observation that 
mast cells migrate into airway smooth muscle (ASM) bundles in asthma, where 
it is thought that they may also contribute to the remodelling response through 
effects on smooth muscle cell proliferation and matrix deposition (44, 45).  
 9 
Tryptase released from mast cells may also contribute to airway remodelling 
through its action on protease-activated receptor type 2 (PAR2).  PAR2 is 
present on many cell types, including epithelial cells, fibroblasts, ASM, and 
inflammatory cells (5) and its activation induces ASM proliferation (46). 
 
As well as its effect on the early asthmatic response, mast cell activation is also 
thought to contribute to the late asthmatic response.  Mast cell activation leads 
to the release from mast cell granules of certain cytokines, including TNF-α, 
IL-4 and IL-5 (47, 48) as well as de novo synthesis, and thus sustained release, 
of certain of these cytokines (49), thereby contributing to continued 
inflammation.  In support of the mast cell’s dual role in the early and late 
asthmatic responses, is the observation that the anti-IgE monoclonal antibody 
omalizumab inhibits both responses (50). 
 
1.3.7  Eosinophils 
Eosinophils are terminally differentiated polymorphonuclear granulocytes 
whose physiological function is to protect the host against large parasitic 
infections.  Maturation of granulocyte precursors in the bone marrow into 
eosinophils is brought about through the sequential action of IL-3 and GM-
CSF, which commit the immature granulocyte to the eosinophil lineage, 
followed by maturation and recruitment to the asthmatic airway under the 
influence of IL-5 and eotaxin (51, 52).  Airway eosinophilia is a consistent 
finding in patients with asthma (53), with the exception of a subgroup of 
patients with severe asthma who may demonstrate mixed eosinophilic and 
neutrophilic inflammation, or neutrophilic inflammation alone (54).  
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Eosinophil numbers correlate with disease severity (53), and the dramatic 
reduction in sputum and tissue eosinophils on treatment of asthma with inhaled 
or oral glucocorticoids, associated with clinical improvement, is the central 
facet of the idea that eosinophils are fundamental to airway dysfunction in 
asthma (55, 56).   Eosinophils contribute to airway inflammation and 
remodelling through the release of several chemokines, cytokines and 
mediators.  Release of chemokines such as regulated on activation, normal T-
cell expressed and secreted (RANTES) and IL-8 promotes recruitment of more 
eosinophils and other inflammatory cells.  A host of cytokines may be released 
by eosinophils (57), which not only have proinflammatory actions on other 
structural and inflammatory cells within the airway, but may also enhance 
eosinophil survival (58).  Perhaps more important, though, are the multiple 
mediators released by eosinophils that can contribute to airway remodelling 
through their direct effects on airway tissues.  Eosinophils synthesise a range of 
cytotoxic mediators, including major basic protein (MBP), eosinophil 
peroxidise (EPO), eosinophil cationic protein (ECP) and eosinophil-derived 
neurotoxin (EDN), that are stored in granules and released on activation.  
Eosinophils and their mediators have been shown to cause direct damage to the 
epithelial layer (59, 60), causing epithelial detachment and cell lysis and 
thereby contributing to airway remodelling (see section 1.4.1.1).  Furthermore, 
MBP causes increased ASM hyperreactivity in vitro (61), and its levels in 
BALF correlate with AHR (62). 
 
The central paradigm that eosinophils are the key cells mediating asthmatic 
airway inflammation and AHR has been challenged recently by the observation 
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that administration of a monoclonal antibody against IL-5, which is essential to 
eosinophil maturation, had negligible effects on airflow and AHR despite a 
greater than 80% reduction in circulating and sputum eosinophils (63).  
However, despite the reduction in blood and sputum eosinophil count, lung 
parenchymal eosinophil levels were reduced to a much lesser degree, leading to 
the suggestion that the remaining eosinophils could account for the continuing 
symptoms (64).  Furthermore, eosinophils entering the airway lumen lose their 
surface receptors for IL-5, but display enhanced levels of receptors for GM-
CSF, another eosinophil activating cytokine, suggesting that eosinophil 
activation in the airways may be IL-5-independent (65).  Interestingly, a recent 
study demonstrated a significant reduction in exacerbations following anti IL-5 
therapy in a population of patients with refractory asthma and eosinophilic 
airway inflammation (66), whilst confirming earlier observations of a lack of 
effect on airflow, symptoms and AHR. 
 
There is certainly evidence to support a role for eosinophils in airway 
remodelling, in that eosinophil depletion significantly reduced deposition of 
several matrix proteins in the subepithelial layer (67).  Further support for a 
role of eosinophils in airway remodelling, but not AHR, comes from the 
observation that in eosinophilic bronchitis, a disease that shares many features 
with asthma but lacks AHR, subepithelial and intraepithelial eosinophil 
infiltration is observed, in association with subepithelial fibrosis (68).  
Undoubtedly eosinophils play an important role in the asthmatic airway, but 
the exact nature of their role remains unclear. 
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1.3.8  Neutrophils 
A subgroup of patients with asthma demonstrate a marked airway neutrophilia 
and this appears to be associated with a more severe phenotype (54, 69).  It has 
been argued that neutrophilic inflammation in severe asthmatics is a 
consequence of treatment, as the majority of these patients take long term oral 
glucocorticoids, which enhance neutrophil survival.  A counterargument to this 
is that the relative steroid resistance of neutrophils may explain the poor 
response to corticosteroids seen in refractory disease.  Interestingly, Ordoñez et 
al found significantly elevated levels of neutrophils, and the neutrophil 
chemokine IL-8, in the tracheal aspirate of patients intubated for acute severe 
asthma, compared to patients intubated electively for non-pulmonary surgery, 
yet, perhaps surprisingly, only five of the ten patients studied were taking 
inhaled corticosteroids or maintenance oral steroids (70), supporting the 
concept that neutrophilic inflammation is a primary feature of severe asthma 
rather than a consequence of therapy.  Furthermore, neutrophil numbers in 
severe asthma correspond to indices of airway damage and reduced 
glucocorticoid responsiveness.(71, 72)  It is thought that this neutrophilic 
phenotype is associated with more aggressive disease resulting in greater tissue 
destruction and airway remodelling.  As described in section 1.4.1.2, mucus 
hypersecretion may contribute to airway narrowing and accelerated decline in 
FEV1 in chronic asthma.  Neutrophils may contribute to this through secretion 
of neutrophil elastase, a potent secretagogue for submucosal gland and goblet 
cells (73). 
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Evidence that neutrophils contribute to airway remodelling comes from a 
number of observations.  Neutrophils from patients with asthma release higher 
levels of the profibrotic cytokine transforming growth factor β (TGFβ) (74).  In 
severe asthma, high levels of a neutrophil-specific form of MMP-9, HMW 
MMP-9, were elevated in BALF and correlated with neutrophil numbers.  
Glucocorticoids were significantly less effective in suppressing HMW MMP-9 
mRNA and protein in severe asthmatics than in controls (75).  Furthermore, the 
ratio of MMP-9 to its endogenous inhibitor, tissue inhibitor of 
metalloproteinase 1 (TIMP-1) was reduced in severe asthma, and correlated 
positively with FEV1 (76).  Thus it seems likely that these cells play a more 
prominent role in severe asthma associated with airway remodelling. 
 
1.3.9  Monocyte macrophages 
Macrophages are derived from circulating monocytes which migrate to the 
lungs in response to chemokines such as monocyte chemotactic protein-1 
(MCP-1), and differentiate into macrophages under the influence of GM-CSF.  
Macrophage numbers are elevated within the airway mucosa of asthmatics 
(77), yet their role in asthma is unclear.  Macrophages are APCs that, when 
activated, can release several mediators that induce bronchoconstriction, such 
as prostaglandins and leukotrienes (78).  They are also a source of tissue 
damaging reactive oxygen species and lysosomal enzymes (5, 78).  
Interestingly, a recent study in a mouse model of asthma found that 
macrophages were the dominant source of the cytokine IL-17 (79).  This 
cytokine is thought to be important in neutrophilic inflammation in asthma 
(discussed in section 1.3.3) and, by inference, this study supports an important 
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role for macrophages in this disease.  In a recent study alveolar macrophages 
were found to be dysfunctional in children with steroid resistant asthma, 
suggesting these cells may be important in corticosteroid-resistant disease (80).  
Overall, however, little is known about the role of macrophages in asthma and 
more studies are required. 
 
1.4  Structural changes in the asthmatic airway 
Chronic inflammation in asthma leads to structural changes in the airways in 
asthma collectively termed airway remodelling.  These changes include 
changes in the epithelium and subepithelial layers, the latter including matrix 
abnormalities and alterations of the airway smooth muscle layer. 
 
1.4.1  Epithelial abnormalities 
1.4.1.1  Epithelial desquamation 
Epithelial denudation has been reported to be increased in biopsy specimens 
and post mortem specimens from patients with asthma compared to healthy 
controls, leading to the hypothesis that disruption of the protective epithelial 
layer results in alterations in host defences and responses to exogenous stimuli 
(81-84).  Further, Chanez et al found that epithelial shedding occurred in 
untreated asthmatics but not in corticosteroid-dependent asthmatics treated 
with oral corticosteroids, or healthy controls (85).   The observation that 
epithelial desquamation occurs in asthma is supported by observations of 
increased numbers of epithelial cells in BALF of patients with asthma (62).  It 
has been proposed that an intrinsic weakness of the epithelial layer in patients 
with asthma contributes to epithelial desquamation.  This hypothesis is 
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supported by the observation that the columnar epithelium lining the bronchi of 
asthmatic patients has less contact area with the basal lamina than in healthy 
controls (86).  Furthermore, electron microscopy studies have also shown a 
reduction in epithelial cell desomosome length in asthmatic patients compared 
with healthy controls (87).   
 
It has been suggested that epithelial desquamation may be an artefact of tissue 
sampling, that is, the biopsy itself may cause damage to the epithelium.  This is 
because some studies of the cellular composition of BALF and sputum have 
shown no difference between numbers of epithelial cells from asthmatic 
patients and healthy controls (88, 89).  Furthermore, one study found both 
epithelium-denuded areas and intact epithelium in bronchial biopsies from 
healthy volunteers and asthmatic patients, with no differences observed 
between the two groups (90).  However, two observations support the 
hypothesis that epithelial damage occurs in vivo.  CD44 is an adhesion 
molecule which is found on basal epithelial cells remaining after damage.  
CD44 immunoreactivity is higher in areas of damaged epithelium.  Lackie et al 
found that expression of CD44+ cells was increased in the epithelium of 
asthmatic patients compared with controls.  Other studies have found elevated 
levels of staining for epidermal growth factor receptor (EGFR), known to be 
involved in epithelial repair processes, in the bronchial epithelium of asthmatic 
patients compared to healthy control subjects (91, 92).  These observations 
support the concept of in vivo epithelial damage in asthma.  Proposed 
mechanisms of bronchial epithelial shedding in asthma include direct toxicity 
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of eosinophil major basic protein to epithelial cells (93, 94) and intrinsic 
weakness of epithelial attachment as discussed above.   
 
Although the widely accepted paradigm in asthma is that it is chronic 
inflammation that leads to airway remodelling, Federov et al have proposed 
that epithelial stress and injury may lead to collagen deposition and 
subepithelial fibrosis, based on their finding of increased EGFR staining in the 
bronchial epithelium of asthmatic children (a marker of epithelial 
activation/injury) associated with increased collagen deposition and thickness 
of the lamina reticularis.  These changes were seen in the absence of any 
increase in eosinophil numbers (92).  In vitro models of epithelial injury have 
been shown to cause increased fibroblast proliferation through release of 
growth factors including fibroblast growth factor (FGF), platelet derived 
growth factor (PDGF), ET-1 and TGF-β (95, 96).  Thus the authors speculate 
that airway remodelling in asthma may occur as a result of epithelial stress, 
independently, to some degree, of inflammation, particularly as the structural 
changes were seen in children, including those with only moderately severe 
asthma. 
 
1.4.1.2  Goblet Cell Hyperplasia 
Asthma exacerbations are frequently characterised by sputum production and, 
furthermore, fatal asthma is commonly associated with mucus plugging of the 
airways (97).  The mechanism of mucus hypersecretion is probably 
multifactorial, but one consistent finding is that of goblet cell hyperplasia in the 
airway epithelium of patients with asthma.  Some studies have found goblet 
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cell hyperplasia to be much more marked in patients who have died from acute 
severe asthma (98), but a more recent study found similar changes in the 
airway epithelium of patients with mild to moderate asthma (99).  The same 
study found that the volume of stored mucin in goblet cells in the airway 
epithelium was higher in asthmatic patients overall than healthy controls, that 
stored mucin levels were (non-significantly) higher in mild than moderate 
asthmatics, and that secreted mucin was significantly higher in moderate than 
mild asthma (99).  This may have important clinical implications, since mucus 
hypersecretion is associated with accelerated decline in forced expiratory 
volume in one second (FEV1) in both non-smokers and smokers with asthma 
(100).  As well as mucus plugging in acute severe asthma, mucus 
hypersecretion may contribute to airway narrowing, meaning that a more 
pronounced effect may be produced for a given degree of smooth muscle 
contraction (bronchoconstriction). 
  
1.4.1.3  Subepithelial fibrosis 
Subepithelial fibrosis refers to the thickening observed in asthmatic airways of 
the layer immediately below the basement membrane.  Multiple studies have 
shown an increase in subepithelial fibrosis in asthma (101-103).  The degree of 
subepithelial fibrosis correlates with the severity (104) but not the duration 
(105) of disease.  Interestingly, although one study found that treatment with an 
inhaled corticosteroid (ICS) for four weeks had no effect on thickness of the 
subepithelial layer (101), another study in which treatment with ICS was 
continued for 12 months showed significant reductions in the thickness of the 
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subepithelial layer (106), suggesting that subepithelial fibrosis is a consequence 
of airway inflammation. 
 
1.4.2  Increased vascularity of the airways in asthma 
Several studies have shown that there is an increase in bronchial wall 
vascularity in asthma.  This has been observed at the macroscopic and 
microscopic level.  Hashimoto et al studied the number of vessels and extent of 
vascularity of the small and medium airways of patients with asthma compared 
to healthy controls (107).  They found that the number of vessels and 
vascularity of the airways was increased in asthmatics.  This difference was 
most marked in the medium airways, where there was also a significantly 
greater degree of vascularity in moderate compared to mild asthmatics.  
Furthermore, vascularity of the medium (but not small) airways was inversely 
correlated with FEV1.  Interestingly, treatment with ICS for one year had no 
effect on vascularity of the asthmatic airways.  This contrasts with other studies 
that found a reduction in airway vascularity following treatment with ICS (108-
110), although the same effect was not observed with a low dose of ICS (109).  
The differences may be due to differences in study populations or in the dose 
of ICS. 
 
A number of candidate angiogenic factors are thought to promote the vascular 
changes seen in asthmatic airways, perhaps the most important of which are 
vascular endothelial growth factor (VEGF) and the angiopoietins, Ang1 and 
Ang2.  These are thought to play distinct but coordinated roles in the 
angiogenic process.  In embryonic development, VEGF is involved in primitive 
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new vessel formation, whereas Ang1, acting at its receptor Tie2, is essential for 
vessel maturation (reviewed in (111)).  Ang2 is in some contexts a natural 
antagonist of Ang1.  Whereas Ang1 is widely expressed in normal tissues, 
Ang2 is expressed mainly at sites of vascular remodelling (112).  Levels of 
VEGF and Ang1, but not the VEGF receptors, VEGFR1 and 2, were shown to 
be significantly higher in bronchial biopsies from patients with asthma 
compared to controls.  VEGF levels were also elevated in the BALF of 
asthmatic subjects (113).  Furthermore, ICS reduced VEGF but not Ang1 
staining in the airways of asthmatics treated with ICS compared with placebo 
(110). 
 
Increased airway vascularity may contribute to the asthma phenotype through 
several mechanisms.  The microvascular bed is a substantial component of the 
airway wall, and even small alterations to the thickness of the inner airway wall 
can contribute to enhanced airway narrowing (114).  Further, the increased 
vasculature may facilitate influx of inflammatory cells and exudation of 
inflammatory mediators, particularly if there is an associated increase in 
vascular permeability.  Finally, the increase in vasculature may contribute to 
AHR by supporting the airway smooth muscle layer, which is thickened in 
asthmatic airways.  An alternative hypothesis is that the increased vasculature 
may have a protective effect by increasing trafficking of inflammatory cells 
and mediators away from sites of inflammation.  The former hypothesis is 
supported by studies in a mouse model of asthma.  Levels of VEGF were 
elevated in the lungs of these mice, and VEGF receptor antagonists inhibited 
inflammatory cell influx and AHR in this model.  Furthermore, some (108, 
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115), but not all (110, 116), studies of ICS and airway vascularity in humans 
have shown an inverse correlation between measures of lung function and 
airway vasculature. 
 
1.4.3  Airway smooth muscle layer 
It is generally accepted that there is an increase in ASM mass in the airways of 
patients with asthma compared to control subjects.  The first study examining 
the amount of ASM in asthmatic airways dates back to 1922 (117).  This study 
compared the airways of patients with fatal asthma to those of patients who had 
died suddenly of non-respiratory conditions.  The authors found an increase in 
smooth muscle layer thickness in the asthmatic group.  Subsequent studies 
have confirmed this finding in patients with fatal asthma (118, 119).  However, 
in cases of non-fatal asthma, increased ASM thickness is a less consistent 
finding with some (118, 120, 121) but not all (119, 122) studies showing an 
increase.   Although such studies are fraught with theoretical technical 
limitations (reviewed in (123)), it is likely that an increase in ASM thickness 
forms part of the remodelling process observed in asthmatic airways, at least in 
severe/fatal asthma. 
 
Similarly, the literature is conflicting regarding whether the increased ASM 
observed in asthmatic airways is due to hypertrophy or hyperplasia of the ASM 
layer.  Woodruff et al found an increase in cell number but not size in the 
airways of patients with mild to moderate asthma compared to normal controls 
(120).  In contrast, another study found that ASM cells were increased in size 
across all asthma groups, that is, those with intermittent, persistent mild-to-
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moderate and persistent severe asthma (121).  A further study defined two 
subgroups of asthmatic patients, one in whom only hyperplasia of the larger 
bronchi was observed, with no evidence of cellular hypertrophy, and a second 
group in whom hypertrophy predominated and was seen at all levels of the 
bronchial tree, with only mild hyperplasia seen (124). 
 
The amount of ASM in the airway is determined by the balance between cell 
proliferation and cell death.  A number of growth factors have been shown to 
promote ASM proliferation in vitro, several of which are found in elevated 
amounts in the asthmatic airway (125).  A less well studied area is ASM cell 
apoptosis.  Freyer et al showed that various components of the extracellular 
matrix (ECM), which is known to be deposited in increased amounts in 
asthmatic airways (126), inhibit ASM cell apoptosis.  The authors postulate 
that this may contribute to airway remodelling in asthma by promoting ASM 
survival and hence contributing to the increased amount of ASM found in the 
asthmatic airway (127). 
 
One further mechanism which may contribute to ASM accumulation in the 
airway is cell migration.  This function of ASM has only recently been 
identified.  Migratory responses of ASM have been observed in vitro (128, 
129) and, furthermore, ASM migration can be modulated by a variety of 
factors, including matrix components (130), growth factors (131), lipid 
mediators (132), glucocorticoids and β2 adrenoceptor agonists (133).  On this 
basis, two hypotheses have been proposed (125).  The first is that ASM cells 
might migrate out of the muscle bundles towards the lumen, thus contributing 
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to the appearance of myofibroblasts in the submucosal space; the second that 
myofibroblasts outside the muscle bundles may migrate toward the bundles, 
precipitating a change of phenotype to that of mature smooth muscle, thus 
adding to its overall content.  Studies of ASM migration are still in their 
infancy and it remains unclear what if any contribution migration makes to 
overall ASM accumulation in the asthmatic airway.  However, if cell migration 
does indeed make a significant contribution to airway remodelling, this would 
provide an exciting new target for therapeutic intervention in asthma. 
 
1.4.4  Functional significance of increased ASM in asthma 
There are several potential functional consequences of an increase in ASM 
amount in asthmatic airways. 
 
1.4.4.1  Reduction in airway calibre and increased force generation 
Early studies concluded that the increase in smooth muscle mass in the airways 
of people with asthma could account for the increased resistance in response to 
bronchoconstrictor stimuli through two mechanisms.  First, the ASM bulk in 
itself, as well as other components of airway remodelling including 
subepithelial fibrosis, would cause a reduction in airway calibre, thus a greater 
degree of airflow limitation would be produced for a given degree of smooth 
muscle contraction (114).  Second, the greater amount of ASM would result in 
a greater degree of bronchoconstriction in response to stimulation (134, 135).  
However, most in vitro studies have not shown an increase in force production 
in response to various stimuli in bronchial preparations from asthmatic patients 
((136) and references therein).  It has been postulated that in vitro force 
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production may not reflect the ability of ASM to shorten, which is thought to 
cause airway narrowing in vivo (137).  There is evidence from animal models 
to support this, in that force generation does not necessarily correlate with 
ability of ASM to shorten (138).  Finally, it has been argued that increased 
shortening velocity, rather than force generation, may be the more important 
determinant of bronchoconstriction in vivo (139). 
 
1.4.4.2  Altered contractility of ASM 
Another possibility is that ASM in the remodelled airway has altered 
contractile properties.  Two potential mechanisms may affect ASM 
contractility: (1) length adaptation, or (2) altered expression or phenotype of 
the smooth muscle contractile apparatus.  The phenomenon of length 
adaptation refers to reduced stretch/length of the muscle, which may occur as a 
consequence of airway wall thickening.  This would allow the muscle to 
chronically adapt to a shorter length, resulting in increased shortening and 
luminal closure upon exposure to bronchoconstrictor stimuli (140).  Many 
investigators have explored the possibility of altered expression or function of 
the contractile apparatus in asthmatic ASM.  Antonissen et al showed an 
increase in the amount and velocity of ASM shortening in a canine model of 
asthma, compared to unsensitised controls (141).  In keeping with this 
observation, canine ASM of sensitised animals was found to have increased 
myosin light chain kinase (MLCK) content and actomyosin ATPase activity 
(142).  More recently, it has been shown that human ASM from asthmatic 
patients expresses greater quantities of MLCK mRNA than controls, with an 
associated increase in shortening capacity and velocity (143).  Similarly, in 
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another study, tissue from asthmatic patients expressed increased MLCK 
compared to controls and levels correlated with asthma severity (121).  In 
contrast, a further study found no difference between asthmatics and controls in 
expression of genes related to a hypercontractile phenotype (120).  However, 
there is in vitro evidence to suggest inflammatory stimuli may augment ASM 
contraction by affecting intracellular calcium signalling, or other mechanisms 
including increased RhoA/Rho kinase pathway activation, persistent β2 
adrenoceptor activation or increased phosphodiesterase 4 expression (reviewed 
in (144)).  It remains unclear whether asthmatic ASM has an intrinsic 
difference in contractile properties, or whether it has normal contractility but 
shortens to a greater extent due to the increased levels of contractile agonists 
and inflammatory mediators liberated in the asthmatic airway.  However, what 
has become clear is that, in addition to its contractile properties, ASM has 
important synthetic functions, which in themselves may contribute in an 
autocrine and paracrine manner to ASM contraction and bronchoconstriction, 
as well as contributing to airway inflammation and remodelling, discussed 
below. 
 
1.4.5 Synthetic functions of ASM 
Over the last decade or so, it has become clear that ASM cells are key 
contributors to the inflammatory and remodelling processes in the asthmatic 
airway (145-147).  This group and others have shown that ASM has important 
synthetic functions and can contribute to chronic inflammation and 
remodelling in chronic asthma  through production of mediators (148-151), 
chemokines (152-157), cytokines (158), growth factors (159), matrix 
 25 
metalloproteinases (160, 161) and angiogenic factors (162).   These factors 
have the capacity to contribute to inflammation and remodelling through a 
variety of mechanisms.  The release of chemokines by ASM contributes to the 
recruitment of inflammatory cells including eosinophils, T-lymphocytes, 
neutrophils, and monocyte-macrophages.  The production of cytokines (158) 
and pro-inflammatory mediators, such as PGE2 (149), provides a mechanism 
by which ASM can act not just on other structural and inflammatory cells in 
the airway, but also in an autocrine manner to further increase release of 
biologically active molecules contributing to inflammation and remodelling 
(152).  Growth factors released by ASM may contribute to remodelling by 
promoting proliferation of structural airway cells.  MMPs selectively degrade 
ECM components; thus, as discussed in section 1.3.8, imbalances between 
MMPs and their inhibitors, TIMPs, may contribute to tissue damage and some 
of the remodelling features seen in asthma.  For example, MMP-9 can degrade 
various components of the ECM thus disrupting the basement membrane and 
potentially increasing the migration of inflammatory cells (163).  MMPs are 
also known to play a role in the trafficking of inflammatory and structural cells 
(164, 165).  Finally, as discussed in section 1.4.2, there is an increase in 
bronchial wall vascularity in patients with asthma (115) suggesting that 
vascular dilatation and proliferation are important components of airway 
remodelling in chronic asthma.  The release of angiogenic factors such as 
VEGF from ASM likely contributes to this process. 
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1.4.6  Differences in ASM between asthmatic and non-asthmatic patients 
Recently, there has been increasing interest in whether there are intrinsic 
differences in ASM from asthmatic patients compared to those without asthma.  
Studies on asthmatic-derived human ASM cells (HASMC) in vitro have 
supported the notion that there are indeed intrinsic differences that persist when 
these cells are cultured in vitro, away from the altered environment within the 
asthmatic airway. 
 
1.4.6.1  Cytokine and mediator release 
A number of studies have explored the release of various cytokines and 
mediators from asthmatic HASMC.  Oliver et al found that rhinovirus-induced 
release of IL-6 and IL-8 was elevated in asthmatic HASMC compared to 
normal controls (166).  This may explain, in part, why many asthma 
exacerbations are triggered by respiratory infections.  Brightling et al found 
that the mast cell chemokine CXCL10 (IP-10) was more frequently expressed 
in the ASM layer of bronchial biopsies of patients with asthma compared to 
non-asthmatic patients.  Furthermore, in ex-vivo cell culture, the asthmatic 
HASMC released significantly greater quantities of CXCL10 following 
stimulation with pro-inflammatory cytokines (44).  This was associated with an 
elevated number of CXCR3 expressing mast cells within the ASM layer in 
bronchial biopsies of patients with asthma.  Mast cells migrated towards 
CXCL10-releasing HASMC in chemotactic assays in vitro, suggesting a 
potentially important mechanism through which mast cell/HASM interactions 
occur in asthma.  The authors suggest that this is of direct relevance to the 
asthma phenotype, since mast cell infiltration into the ASM layer is not 
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observed in eosinophilic bronchitis, a condition related to asthma that presents 
with a glucocorticoid responsive cough, but lacks the variable airflow 
obstruction observed in asthma.  Since mast cells are a source of a number of 
factors that can induce ASM proliferation, hyperresponsiveness and 
contraction, the differential production of CXCL10 by asthmatic HASMC may 
be an important determinant of the asthma phenotype.  Another study 
comparing HASMC from asthmatic individuals and normal controls found that 
trypsin and bradykinin-induced PGE2 release was reduced in proliferating, but 
not quiescent, asthmatic ASM (167).  The authors speculate that, since PGE2 
can inhibit HASM proliferation, this could partly explain increased ASM 
proliferation observed in asthmatic cells.  Furthermore, PGE2 has anti-
inflammatory properties, so defective release from proliferating asthmatic 
ASM could contribute to airway inflammation. 
 
1.4.6.2  ASM proliferation 
Ex-vivo, cultured HASMC from asthmatic patients have been shown to 
proliferate significantly more rapidly than those from normal controls (168), 
which may explain, in part, the increase in smooth muscle mass in the 
asthmatic airway.  There is evidence that the mechanism of disordered 
proliferation is due to a deficiency of the transcription factor CCAAT/enhancer 
binding protein-α (C/EBPα) in these cells (169).  In ASM from non-asthmatic 
subjects, C/EBPα mediates the antiproliferative effects of glucocorticoids.  In 
HASMC from asthmatic patients, C/EBPα was not expressed, and 
glucocorticoids failed to inhibit cell proliferation.  Transfection of asthmatic 
HASMC with a C/EBPα expression vector restored glucocorticoid 
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antiproliferative effects.  There is some evidence to suggest that the cell 
signalling pathways responsible for ASM proliferation also differ between 
asthmatics and non-asthmatics.  Burgess et al found that ASM cell proliferation 
was mediated by both extracellular signal-regulated kinase (ERK) and 
phosphatidylinositol 3-kinase (PI3K) in asthmatic and non-asthmatic ASM.  
However, in the presence of a strong mitogenic stimulus, signalling in 
asthmatic ASM shifted towards a PI3K-mediated pathway, raising the 
possibility of specific targeting of this pathway in the prevention or treatment 
of airway remodelling (170).  Interestingly, elevated levels of the nuclear 
hormone receptor peroxisome proliferator activated receptpor γ (PPARγ) have 
been demonstrated in the bronchial submucosa, the airway epithelium, and 
ASM of steroid-untreated asthmatics, and this is associated with enhanced 
proliferation and apoptosis of airway epithelial and submucosal cells, but not 
ASM (171).  The authors speculate that PPARγ may have pro-inflammatory 
and fibrotic actions, in contrast to the prevalent view of PPARs as anti-
inflammatory. 
 
1.4.6.3  ASM extracellular matrix interactions 
The ASM is surrounded by the ECM, which consists of an array of structural 
matrix proteins, including collagens, laminins, elastin and chondroitin sulphate, 
matrix-degrading MMPs and TIMPs.  The ECM is a dynamic structure, with a 
turnover rate of around 10 – 15% per day.  Degradation of the ECM releases 
factors which can feed back on ASM.  The complex interaction between ASM 
the ECM is exemplified by the observation that certain ECM components 
inhibit whereas others increase growth factor-stimulated ASM proliferation 
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((172) and references therein).  As mentioned above, the ECM is deposited in 
increased amounts in the asthmatic airway.  In keeping with this, asthmatic 
ASM cells in vitro produced altered amounts of ECM components compared to 
non-asthmatic cells, and this altered ECM enhanced proliferation of both 
asthmatic and non-asthmatic ASM (173).  Furthermore, like ASM 
proliferation, PI3K was involved in TGF-β-stimulated fibronectin and collagen 
I production in asthmatic but not non-asthmatic ASM, again suggesting this 
pathway may be of therapeutic interest (174). 
 
1.4.7  Airway smooth muscle/T-cell interactions 
In section 1.3 we discussed the roles of T-cells in asthma.  Interestingly, 
activated T-cells can bind to ASM cells in vitro via CD44 expressed on the 
ASM cell surface and may stimulate ASM proliferation (175).  ASM also 
express other surface receptors with the potential to bind to T-cells (176, 177).  
These observations suggest that ASM-T-cell interactions may be important in 
asthmatic airway inflammation.  However, in vivo evidence for such 
interactions is currently lacking. 
 
1.5  Mediator component of asthma 
As has been alluded to in our discussion of the roles of inflammatory and 
structural cells in asthma, a range of mediators are secreted by these cells 
including histamine, adenosine, 5-hydroxytriptamine, lipid mediators 
(prostaglandins, thromboxanes), leukotrienes, and peptide mediators such as 
endothelin-1 (ET-1) and bradykinin (BK).  These mediators have multiple 
overlapping actions, including triggering bronchoconstriction, promitotic 
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effects on ASM and other airway structural cells, pro-inflammatory effects and 
effects on airway remodelling.  It is beyond the scope of this introduction to 
review this vast area in detail; this has been done elsewhere (178).  In this 
thesis, we have focused on the role of the peptide mediator ET-1.   
 
1.5.1  Mediator signalling 
Many of the important mediators in asthmatic airway inflammation signal 
through seven-transmembrane G-protein coupled receptors (GPCRs).  On their 
cytoplasmic domain, GPCRs are associated with heterotrimeric G proteins 
composed of a Gα subunit and a Gβγ subunit.  Binding of an agonist to the 
GPCR results in a change in receptor conformation, triggering exchange of 
bound GDP on the Gα surface for GTP, and dissociation of Gβγ from Gα.  This 
promotes interaction of the Gα subunit with its specific effector, resulting in 
generation of second messengers and triggering an intracellular signalling 
cascade and cellular response. 
 
 Gα proteins are classified depending on the second messenger system with 
which they interact.  Gαs activates adenylyl cyclase (AC) resulting in 
generation of cyclic adenosine monophosphate (cAMP) and protein kinase A 
(PKA) activation.  Gαi inhibits AC, Gαq activates calcium and inositol 
phosphate dependent pathways via phospholipase C, and can also activate 
PI3K, and Gα12/13 couples to the Rho family of guanine nucleotide exchange 
factors.  The classic example of a GPCR-mediated response is that of the β-
adrenergic receptor.  Binding of a β-adrenergic agonist such as salbutamol 
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results in activation of AC via Gαs, generation of cAMP and, in the airway, 
relaxation of bronchial smooth muscle. 
 
It is clear that many mediators important in asthma can upregulate the 
expression of inflammatory response genes.  For example, the Knox group has 
shown that bradykinin induces cyclooxygenase 2 (COX-2), VEGF and IL-8 
expression in HASMC (152, 162, 179), others have shown that leukotrienes 
induce chemokine and cytokine expression in mononuclear cells (180, 181).  
However, the signalling pathways leading to inflammatory response gene 
expression in response to GPCR agonists have not been well characterised and, 
in particular, the nuclear signalling events are poorly understood. 
 
Inflammatory gene expression is regulated at several levels. These include 
activation of transcription factors, such as nuclear factor κB (NF-κB), via 
kinase cascades, binding of transcription factors to specific recognition 
elements in gene promoters, by chromatin remodelling, and through post-
transcriptional modification.  Transcriptional activation is particularly 
complex.  DNA in its native state exists as chromatin and is wound around four 
core histones (H2A, H2B, H3, H4).  These histones undergo a number of 
covalent modifications (acetylation, phosphorylation, methylation) which 
regulate chromatin unwinding thereby allowing access of transcription factors 
to their binding sites on DNA, recruitment of essential co-factors and activation 
of transcription.  Histone acetylation is brought about by histone 
acetlyltransferases (HATs) such as cAMP response element binding protein 
(CREB) binding protein (CBP), p300 and p300/CBP associated factor (pCAF).  
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This process is reversed through the actions of a class of counterregulatory 
proteins, the histone deacetylases, or HDACs.   
 
The Knox group has explored some of the signalling events involved in 
induction of IL-8 and COX-2 expression by BK.  NF-κB, activator protein-1 
(AP-1) and NF-IL-6 are all involved in IL-8 induction by BK (182).  In 
contrast BK induced COX-2 via the cAMP response element (CRE) with no 
involvement of NF-κB or NF-IL-6 (183).  In this latter study, BK-induced 
COX-2 transcription was found to involve acetylation of promoter-associated 
histones on lysine residues 5, 8 and 16 (183).  Complex autocrine loops 
involving endogenous prostanoids seem to be responsible for some of these 
effects but not others (182, 183). The Knox group also showed that another 
important inflammatory mediator in asthma, PGE2, transcriptionally 
upregulates VEGF production in HASMC through a cAMP dependent 
mechanism.  This effect was mediated through binding of the transcription 
factor small protein 1 (Sp1) to the VEGF promoter, demonstrated by chromatin 
immunoprecipitation (ChIP) assay (184). 
 
A number of studies have shown that the pro-inflammatory transcription 
factors NF-κB and AP-1 may be activated by a variety of inflammatory 
mediators, including leukotrienes (181, 185), histamine (186) and 
prostaglandins (187).  However, the majority of these studies used strategies 
such as transcription factor mRNA levels, reporter gene assays and 
electrophoretic mobility shift assays to infer involvement of these transcription 
factors.  Very few studies have gone on to demonstrate in vivo binding of 
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transcription factors to the relevant gene promoters using, for example, ChIP 
assays.  Furthermore, more complex transcriptional mechanisms involving 
recruitment of cofactors (such as p300) to gene promoters, and chromatin 
remodelling in the form of histone modifications, have not been explored, and 
the upstream signalling pathways are not well characterised.  Aside from the 
studies of BK effects from this lab, an exception to this is in the field of 
endocrinology, where binding of histone-modifying proteins and alterations in 
histone acetylation status of relevant promoters have been demonstrated in 
prostaglandin-regulated ovarian luteolysis and oestrogen biosynthesis (188, 
189). 
 
It is well established that mediators acting at GPCRs can activate various 
intracellular signalling pathways downstream of second messenger systems.  
For example, in pulmonary artery smooth muscle cells, PI3K and p38 MAPK 
regulate BK-stimulated PGE2 release (190) and ET-1 can activate the MEK 
(MAPK/ERK kinase)/ERK, p38 MAPK and cJun N-terminal kinase (JNK) 
pathways in various systems (191, 192).  Other intracellular targets include 
protein kinase C (PKC) and phospholipase A2 (PLA2) (193).  Furthermore, 
Gαs-stimulated PKA activation may have inhibitory effects on MAPK 
dependent pathways via phosphorylation and inhibition of the upstream 
intermediate raf-1 (193).  However, there have been few studies directly 
linking these signalling cascades with nuclear gene expression events. 
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1.5.2  Endothelin-1 
ET-1 is a 21 amino acid vasoactive and pro-inflammatory peptide that acts at 
Gαq-coupled ETA and ETB receptors.  ET-1 is implicated in asthma through 
several lines of evidence:  1) ET-1 levels are elevated in BALF, bronchial 
biopsies and peripheral blood of asthmatics (194); 2) inhaled ET-1 causes 
bronchoconstriction in asthmatic patients (195); 3) ET-1 is a potent contractile 
agonist of isolated human bronchus (196); 4) ET-1 potentiates mitogenic 
responses in cultured ASM cells (197); 5) ET-1 induces expression of matrix 
proteins by pulmonary fibroblasts (191), suggesting a role in airway 
remodelling; 6) in animal models, overexpression of ET-1 in the lungs of 
transgenic mice induces chronic pulmonary inflammation (198) and in a rat 
model, induction of pulmonary eosinophilic inflammation caused a significant 
increase in ET-1 mRNA and protein (199).  Furthermore, the ET-1 receptor 
antagonist SB-217242 inhibits airway eosinophilia and hyperresponsiveness to 
methacholine in Der P1 sensitised mice (200).  7) ET-1 and ETA receptor gene 
polymorphisms are linked with asthma and atopy respectively (201, 202).  
Despite the implication of ET-1 in airway inflammation through animal 
studies, there have been very few studies of ET-1’s effects on release of 
inflammatory cytokines and mediators from ASM.  Furthermore, there have 
been few studies of nuclear signalling by ET-1 and the transcriptional and post-
transcriptional regulation of chemokine expression by ET-1 has not been 
studied.  The current understanding of cell signalling and transcriptional 
regulation by ET-1 is described in more detail in chapter 4.  In that chapter, we 
have explored the transcriptional regulation of inflammatory genes by ET-1 in 
more detail, focusing on the chemokine MCP-1. 
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1.6  Cytokines 
The immune system is regulated by a bewildering array of cytokines.  
Cytokines are small proteins that act in an autocrine and paracrine manner to 
regulate local and systemic immune and inflammatory responses.  They 
function in a complex network where production of one cytokine will influence 
the production of, or response to, several others, often in a stimulus and tissue-
specific manner.  Their many actions include effects on growth, mobility, 
differentiation or function of target cells (178). Cytokines act by binding to 
specific cell surface receptors.  Receptor binding leads to activation of 
intracellular signalling pathways and downstream effects, such as induction of 
inflammatory response genes (148, 203).  Levels of many cytokines thought to 
be important in asthma are elevated in the airways of asthmatic patients (9, 10, 
14, 30) and, in earlier sections of this chapter, we have touched on the 
functions of some of these.  We focus in this thesis on the role of TNF-α.  A 
review of the functions of other individual cytokines in asthma has been 
performed by Barnes (178). 
 
1.6.1  Tumour necrosis factor-α 
TNF-α is a 17 kDa protein which acts via two receptors, TNFR1 or p55, and 
TNFR2 or p75.  It is produced predominantly by macrophages, but also T-
lymphocytes, dendritic cells, mast cells, neutrophils and eosinophils as well as 
structural cells including fibroblasts, epithelial cells and smooth muscle cells 
(178, 204).  Release of TNF-α may be triggered by pathogens, physical or 
chemical stimuli, and a range of cytokines such as IL-1, GM-CSF and IFN-γ 
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(178). The physiological role of TNF-α is to modulate the growth, 
differentiation and proliferation of a range of cell types as well as mediating 
apoptosis (205).  It also triggers the release of various other members of the 
cytokine network such as IL-8 (154), RANTES (206) and eotaxin (203), 
thereby triggering a “second wave” of inflammatory responses. 
 
TNF-α levels are elevated in the BALF and bronchial biopsies of asthmatic 
patients (207, 208).  Furthermore, cells from BALF of asthmatic patients 
release significantly greater amounts of TNF-α (14).  As mentioned above, 
once released in the airways, TNF-α can activate the release of multiple 
inflammatory mediators, chemokines and cytokines, thus promoting ongoing 
inflammation.  There is also evidence for a direct role of TNF-α in airway 
remodelling in that it stimulates the release of MMP-9 and the matrix protein 
tenascin from bronchial fibroblasts (209).  TNF-α promotes AHR; TNF-α 
increased maximal isotonic contraction to methacholine of guinea pig tracheal 
preparations in vitro (210).  In animal studies, TNF-α has been shown to 
mediate LPS and allergen-induced inflammation and AHR (211, 212).  
Furthermore, TNF-α inhalation increases airway responsiveness and induces 
sputum neutrophilia in normal controls (213) and asthmatic patients (214), the 
latter group also showing an increase in sputum eosinophilia.  Importantly, 
there is evidence of upregulation of the TNF-α pathway and increased mucosal 
TNF-α expression in severe/refractory asthma (215, 216) which has led to 
increasing interest in the use of anti-TNF-α treatments for patients with severe 
asthma whose disease cannot be controlled with conventional therapies (see 
section 1.9.2). 
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Most cytokine receptors are associated with molecules called Janus kinases 
(JAKs).  Receptor binding causes tyrosine phosphorylation and subsequent 
activation of JAKs.  JAKs may then activate various signalling proteins, 
including signal transducers and activators of transcription (STATs), through 
tyrosine phosphorylation.  STAT dimers then translocate to the nucleus where  
they bind to the promoters of and activate cytokine responsive genes.  TNF-α 
does not signal through the JAK-STAT pathway.  Binding of TNF-α to its 
receptor initiates one of many potential intracellular signalling cascades 
depending on the exact tissue and the expression pattern of associated 
signalling machinery (217).  There are two main pathways of signal 
transduction between the TNFRs and subsequent intracellular events.  TNFR1 
contains a “death domain” (DD) which, under quiescent conditions, is bound to 
the silencer of death domain (SODD).  On binding of TNF-α, SODD 
dissociates from the receptor, allowing other DD-interacting proteins to bind 
and trigger a cascade of reactions primarily involved in signalling cell death.  
However, it is the second pathway that is probably more relevant in the 
activation of inflammatory response genes.  Both TNFR1 and TNFR2 contain 
sequences that bind TNF receptor-associating factors (TRAFs).  Upon receptor 
occupation by TNF-α, TRAFs transduce this signal to activate a variety of 
intracellular signalling pathways, including activation of MAP kinase pathways 
(p38, MEK/ERK and JNK pathways), activation of phospholipase C (PLC) and 
thence PKC, and activation of the pro-inflammatory transcription factors 
NF-κB and AP-1 (217-219). 
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In contrast to GPCR-mediated inflammatory gene regulation, transcriptional 
regulation of inflammatory genes by cytokines such as TNF-α has been more 
extensively studied.  There have been many studies of the roles of various 
transcription factors in inflammatory gene regulation by cytokines.  More 
recently, a number of groups have begun to extend these studies to explore the 
role of histone modifications such as phosphorylation and acetylation and the 
roles of the transcriptional co-activators that bring these modifications about.  
For example, IL-1β induced COX-2 transcription in HASMC through binding 
of p65, CREB and C/EBPβ, and acetylation of lysine 8 associated with the 
COX-2 promoter (183).  Similarly, IL-1β caused histone acetylation at the 
GM-CSF promoter, accompanied by an increase in GM-CSF release from 
A549 cells (220).  Several studies have investigated the transcriptional 
regulation of the chemokines MCP-1 and eotaxin in various systems.  
Transcriptional regulation of MCP-1 by the cytokines IL-1β and TNF-α has 
been shown to be NF-κB-dependent in several different tissues (221-223).  
Interestingly, in NIH 3T3 cells, TNF-α-stimulated MCP-1 transcription 
involves a cooperative interaction between NF-κB and Sp1 that is dependent 
upon CBP and p300-mediated histone acetylation at the MCP-1 promoter (222, 
223).   The Knox group have shown that transcriptional regulation of eotaxin 
by TNF-α in HASMC is brought about through acetylation of histone H4 and 
binding of NF-κB p65 to the eotaxin promoter (224).   
 
Although inflammatory response gene regulation by cytokines is better 
characterised than that mediated by GPCRs, and although there is a wealth of 
studies on TNF-α-signalling (217), the exact kinase cascades mediating 
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complex gene transcription events are less clear.  There is evidence, in various 
different biological systems, for involvement of JNK, ERK and p38 MAP 
kinases in these pathways (225, 226), as well as for involvement of the 
PI3K/Akt pathway (227) and of PKC (228, 229).  Indeed, the Knox group have 
shown that transcriptional regulation of eotaxin by TNF-α involves PKCβ-
mediated phosphorylation of pCAF, facilitating acetylation of histone H4 and 
thence p65 association with the eotaxin promoter (228).  This is a novel action 
of PKCβ that has not been previously observed in other systems.  MAP kinase 
cascades can also lead to histone phosphorylation through the direct action of 
downstream kinases such as mitogen- and stress-activated protein kinase 
(MSK). 
 
1.7  Inflammatory gene regulation:  cross talk between cytokine- and 
GPCR-mediated pathways  
It is clear that transcriptional gene regulation by inflammatory mediators and 
cytokines is extremely complex.  The involvement of common signalling 
moieties to both GPCR- and cytokine-mediated pathways implies that 
extensive cross talk may occur.  Indeed there is evidence that this is the case.  
Histamine, which couples to AC and PI3K pathways through H2 and H1 
receptors respectively, may regulate release of the cytokine IL-13 in T cells 
through cross-talk with the JAK-STAT pathway (230).  As previously 
discussed, PGE2, which acts via Gαs-coupled receptors, modulates cytokine-
stimulated induction of VEGF and COX-2 (183, 231). Furthermore, mitogenic 
signals acting at receptor tyrosine kinases (epidermal growth factor) and 
GPCRs (thrombin, acting at the Gαq-coupled PAR) both signal through PI3K in 
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HASMC (232).  Finally, BK-stimulated IL-6 release in HASMC is mediated 
by p38 MAPK and ERK, and is downregulated by the Th2 cytokines IL-4 and 
IL-13, implying that MAP kinases may also mediate cross talk between GPCR- 
and cytokine-stimulated responses (233). 
 
In addition to the complex cross talk between different pro-inflammatory 
stimuli, evidence is accumulating that existing asthma therapies, including 
glucocorticoids (GC) and long acting β-adrenergic agonists (LABA) can 
modulate these inflammatory pathways.  This is discussed in detail in section 
1.9.1 and chapter 5.  A simplified representation of GPCR- and cytokine-
mediated inflammatory gene regulation, potential points of cross-talk, and of 
modulation by existing asthma therapies is shown in Figure 1.1.  In chapter 5 
we have further explored the mechanisms of TNF-α-stimulated eotaxin 
expression, and its modulation by glucocorticoids and long acting β-adrenergic 
agonists (LABA). 
 
1.8  Chemokines 
Chemokines are a subgroup of cytokines that attract inflammatory cells 
(chemotactic cytokines).  Examples include MCP-1 (chemotactic for 
monocytes and T-lymphocytes), RANTES (T-cells, eosinophils and basophils), 
eotaxin (eosinophils) and IL-8 (neutrophils).  Chemokines exert their biological 
actions by binding to specific receptors expressed on the surfaces of target 
cells.  Cells that are attracted by chemokines follow a signal of increasing 
chemokine concentration towards the source of the chemokine through a 
complex process involving interaction of adhesion molecules expressed on the 
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surfaces of inflammatory and endothelial cells (234).  Thus at sites of 
inflammation such as the asthmatic airway, release of chemokines from 
inflammatory and structural cells results in further influx of inflammatory cells 
and perpetuation of inflammation.  Chemokines are classified on the basis of 
their structural characteristics, specifically the distance between the first two 
cysteine residues in their amino acid chain (235).  Thus the two cysteine 
residues at the N-terminus of the CC chemokines are adjacent to one another, 
those of the CXC chemokines are separated by one amino acid, and those of 
the CX3C group by three amino acids.  A fourth group, with one cysteine 
residue at their N-terminus and one downstream are termed the C chemokines.  
This has led to a revised nomenclature based on these structural characteristics 
(235).  Thus for the chemokines listed above, the alternate names would be 
CCL2 (MCP-1), CCL5 (RANTES), CCL11 (eotaxin) and CXCL8 (IL-8).  For 
the purpose of readability, the classical names will be used in this thesis.  The 
chemokine receptors are GPCRs divided into four families based on the class 
of chemokine they bind; CXCR that bind CXC chemokines, CCR that bind CC 
chemokines, XCR1 that binds the two C chemokines and CX3R1 that binds the 
sole CX3C chemokine.  An individual receptor may bind several different 
chemokines and vice versa.  In this thesis we have explored the regulation of 
two key chemokines in the asthmatic airway, MCP-1 and eotaxin. 
 
1.8.1  MCP-1 and asthma 
MCP-1 is a chemokine of the CC subgroup which is chemotactic for 
monocytes (236, 237) and T-lymphocytes (238, 239).  It is produced by a 
variety of cell types, including mononuclear phagocytes, epithelial cells, 
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fibroblasts, smooth muscle cells and endothelial cells (240-244).  Levels of 
MCP-1 are elevated in the epithelium and subepithelial tissues of bronchial 
biopsies from asthmatic subjects, including the bronchial smooth muscle layer 
(245).  Allergen challenge significantly increased MCP-1 levels in BALF of 
asthmatic patients (246).  Furthermore, there is evidence from animal models 
that MCP-1 expression is increased in asthmatic airways and that the disease 
process is attenuated by MCP-1 immunoneutralisation (247).  Interestingly, a 
polymorphism in the MCP-1 gene is associated with the presence of atopic 
asthma and its severity in children (248).  These observations suggest that 
MCP-1 is an important chemokine contributing to airway inflammation in 
asthma.  The Knox group and others have shown that HASMC express MCP-1 
and that levels of expression are upregulated by cytokines (242, 249, 250).  
However, there have been few studies in ASM of the effects on MCP-1 
expression by other types of asthma mediators.  In chapter 4 we explore the 
mechanisms used by the pro-inflammatory mediator ET-1 to upregulate MCP-
1 expression in HASMC. 
 
1.8.2  Eotaxin and asthma 
As described in section 1.3.7, eosinophils are important cells in asthmatic 
airway inflammation.  Eotaxin is chemotactic for eosinophils in vivo and in 
vitro (251, 252).  It also exerts chemotactic actions on basophils (253), Th2 
lymphocytes (254) and mast cells (255), through its specific receptor CCR3.  
Sources of eotaxin include monocyte-macrophages, T-cells, eosinophils, 
airway epithelial cells and ASM cells (256-258). Several lines of evidence 
support a critical role for eotaxin in asthmatic airway inflammation.  Levels of 
 43 
eotaxin are elevated in the bronchial mucosa and BALF of asthmatic subjects 
compared with normal controls (256-258), eotaxin expression correlates with 
the number of airway eosinophils, markers of disease severity and AHR (257, 
258), and the time course of eotaxin expression in the asthmatic airway 
following allergen challenge correlates with the early phase of eosinophil 
recruitment (259).  Furthermore, eotaxin release from airway epithelial and 
smooth muscle cells is increased in vitro by the pro-inflammatory cytokines 
IL-1β and TNF-α, the levels of which are elevated in the asthmatic airway 
(207, 208).  The Knox group and others have shown that eotaxin expression by 
HASMC is downregulated by existing asthma therapies, namely β2 adrenergic 
agonists and glucocorticoids (203, 260).  We have begun to explore the 
mechanisms of TNF-α-stimulated eotaxin expression in HASMC and its 
modulation by glucocorticoids and LABA in more detail (224).  In chapter 5 
we have extended these studies to investigate these mechanisms further. 
 
1.9  Current asthma treatments 
Asthma treatments can be divided into those that primarily affect 
bronchoconstriction, used in the short term relief of symptoms and for 
managing severe bronchospasm in the acute setting, and those that are 
primarily aimed at controlling airway inflammation.  Those in the first group 
include short-acting β2 adrenergic agonists (SABA), such as salbutamol, 
formotorol and terbutaline, and anticholinergics such as ipratropium bromide.  
SABA promote smooth muscle relaxation through binding to the β2 adrenergic 
GPCR, activation of AC and generation of intracellular cAMP.  This acts via 
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PKA to inhibit MLCK.  Anticholinergics block muscarinic cholinergic 
receptors, thus reducing ASM tone by reducing parasympathetic stimulation. 
 
Other classes of drugs used to treat asthma include LABA such as salmeterol 
and formotorol (which has both short and long acting properties), xanthines, 
namely theophylline, leukotriene antagonists, such as montelukast and 
zafirlukast and chromones including sodium chromoglicate and necrodomil.  
The LABA act like SABA to relax ASM but, as the name suggests, have a 
longer duration of action.  However, they also likely have anti-inflammatory 
actions; the anti-inflammatory effects of LABA are discussed in more detail in 
chapter 5.  The current British Thoracic Society guidelines on the management 
of asthma recommend that LABA are prescribed in addition to inhaled 
corticosteroids (ICS) (261).  They should not be prescribed alone due to 
concerns over safety (262).  Theophylline relaxes airway smooth muscle 
through elevation of intracellular cAMP and cyclic guanosine monophosphate 
via inhibition of phosphodiesterases (PDE) 3, 4 and 5 (263).  Unfortunately it 
has limited efficacy and, due to its narrow therapeutic window, has an 
extensive side effect profile at doses that inhibit PDE, meaning its usefulness in 
the management of asthma has been limited.  However, there is emerging 
interest in more recently recognised anti-inflammatory effects of low dose 
theophylline, and this drug may yet prove to have therapeutic utility in the 
management of asthma and COPD in certain circumstances (263-265).  
Leukotrienes are potent mediators of bronchoconstriction (266) as well as 
having multiple pro-inflammatory actions in vivo, including inflammatory cell 
recruitment and increases in vascular permeability and mucus secretion (267-
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270).  Leukotriene antagonists improve baseline lung function in asthmatic 
patients (178), but are probably most useful in the clinical setting as an add on 
therapy for patients with exercise induced asthma (178, 261), or those with 
disease with a prominent leukotriene-driven component, that is those with 
aspirin induced asthma or asthma associated with allergic rhinitis (271).  
Sodium chromoglicate and necrodomil are said to be “mast cell stabilisers”, but 
their mechanism of action is not fully understood.  Their role in adults is 
limited to the management of exercise induced asthma (261). 
 
1.9.1  Glucocorticoids 
Inhaled corticosteroids are the mainstay of asthma treatment.  They are highly 
effective and are recommended for the management of any patient with asthma 
who has symptoms requiring more than just occasional use of a SABA (261).  
They have potent anti-inflammatory effects, thereby inhibiting ongoing 
inflammation in the asthmatic airway and the late allergic response.  The 
mechanisms through which glucocorticoids (GC) achieve their effects are 
complex.  They can both activate and inhibit transcription of GC-responsive 
genes (transactivation and transrepression, respectively). 
 
As described in section 1.5.1, inflammatory gene regulation may involve 
activation of transcription factors, such as NF-κB, via kinase cascades, binding 
of transcription factors to gene promoters, chromatin remodelling brought 
about through specific covalent modifications to histone proteins, and post-
transcriptional modification.  Transactivation by GC is brought about through 
binding of GC to a ubiquitously expressed glucocorticoid receptor (GR) 
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localized to the cytoplasm of target cells.  Binding of GC to GR results in 
dissociation of the molecular chaperone protein hsp90 from GR, allowing 
nuclear translocation of the activated GC-GR complex and binding to specific 
sequences within DNA termed glucocorticoid response elements (GRE).  
Within the nucleus, the DNA binding domain of the GR directs dimerisation 
and activation of gene transcription.  The expression of a number of anti-
inflammatory genes such as annexin 1 and IL-10 has been shown to be 
increased by GC (272, 273).  However, the majority of anti-inflammatory 
effects of GC are thought to be brought about through gene repression. 
 
Switching off of gene transcription by GR can occur through binding of GR to 
negative GREs in the regulatory region of certain genes.  This is thought to 
disrupt transcription as a result of the GRE being positioned across the 
transcriptional start site or the binding sites for other transcription factors 
(274).  However, although a functional negative GRE has been identified in the 
IL-1β promoter (275), the genes of most inflammatory mediators that are 
suppressed by GC in asthma do not have GREs in their promoters (276). 
 
The inhibitory effect of GC in inflammation appears to be largely due to 
modulation of transcription of AP-1- and NF-κB-responsive genes.  These 
transcription factors mediate the expression of multiple inflammatory response 
genes (277, 278).  Alterations in AP-1 and NF-κB-dependent transcription can 
be brought about at several levels.  GR can recruit nuclear corepressors, such 
as HDACs (220); it may alter RNA polymerase II phosphorylation (279); it 
may bind to transcriptional coactivators such as CBP thus competing with 
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transcription factor binding to these coactivators (280);  or GR may inhibit the 
activity of HATs such as CBP (220).  The effects of GC on HAT and HDAC 
activity and associated effects on chromatin structure and transcriptional 
activation are discussed further in chapter 5.  Several other mechanisms of GR 
suppression of NF-κB and AP-1 have been described.  GR can induce 
expression of inhibitor of κBα (IκBα) in certain cell types (281, 282).  AP-1-
DNA binding can be prevented through induction of the glucocorticoid 
inducible gene GILZ (glucocorticoid inducible leucine zipper) (283).  Finally, 
GC may inhibit activation of AP-1 and NF-κB through inhibitory effects on 
mitogen activated protein kinases (MAPK) (276).  Whilst most of the effects of 
GC are mediated by changes in gene transcription, they may also have post 
transcriptional, translational and non-genomic actions (274, 284). 
 
1.9.2  Limitations of current asthma treatments 
Whilst for the majority of patients with asthma, adequate control of disease can 
be achieved with the inhaled therapies described above, a minority of patients 
require long term oral corticosteroids to control their disease, or have 
corticosteroid resistant (CR) disease.  These patients are at increased risk of 
death from asthma and from side effects of chronic systemic steroid therapy, 
and account for around 50% of the total health care costs of asthma (274).  As 
well as their anti-inflammatory effects, steroids have a role in many metabolic 
processes.  Thus long term steroid treatment in those with steroid dependent 
disease can cause serious systemic side effects including adrenal insufficiency 
due to suppression of the hypothalamic-pituitary-adrenal axis, osteoporosis, 
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impaired glucose tolerance/diabetes mellitus, cataracts and, in children, growth 
retardation. 
 
There is much research interest in mechanisms of steroid resistance in asthma.  
A number of different potential mechanisms have been described, that are 
likely to differ between patients.  Certain cytokines, such as IL-2, IL-4 and IL-
13, which show increased expression in the airways of patients with CR asthma 
(274), may induce reduced GR affinity in inflammatory cells, causing local 
resistance to the anti-inflammatory effects of GC (285, 286).   This effect 
appears to be mediated by p38 MAPK, raising the possibility that p38 MAPK 
inhibitors may have a role in restoring steroid sensitivity in CR asthma (287).  
Furthermore, MAP kinase phosphatase-1 (MKP-1), which dephosphorylates 
and inactivates p38 MAPK, is rapidly induced by GC (288).  Thus p38/MKP-1 
homeostasis might be important in contributing to steroid insensitivity.  
Changes in GR nuclear translocation or its ability to interact with HATs may 
contribute to steroid resistance.  In one subgroup of CR patients, nuclear 
translocation of GR was defective (289). In another group, GR was unable to 
promote acetylation of lysine 5 on histone H4, leading the authors to speculate 
that this defect reduces the ability of GR to activate certain anti-inflammatory 
genes (289).  Increased levels and/or activation of the proinflammatory 
transcription factor AP-1 may contribute to steroid insensitivity in CR asthma.  
Expression of the AP-1 subunit cFos is enhanced in bronchial biopsies of CR 
asthmatics (290).  In keeping with a role for AP-1 in CR asthma, AP-1 DNA 
binding and cFos expression were increased in peripheral blood mononuclear 
cells (PBMC) from CR patients, and cFos was shown to mediate reduced GR-
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GRE binding in response to dexamethasone (291, 292).  Further support for a 
role of AP-1 comes from the observation that using a tuberculin skin response 
model of mononuclear cell inflammation, there was significantly greater 
expression of cFos, phosphorylated cJun and phosphorylated JNK in CR 
asthmatics, and, whilst CS suppressed cJun and JNK phosphorylation in steroid 
sensitive asthmatics, they enhanced it in the CR group (293).  As discussed in 
section 1.4.6.2, defective expression of the transcription factor C/EBP in 
asthma may prevent the antiproliferative effects of GC on ASM (169).  Finally, 
cigarette smoking is known to abolish the therapeutic response to inhaled and 
oral corticosteroids, (294, 295).  Cigarette smoke causes oxidative stress and, 
interestingly, markers of oxidative stress are also increased in severe CR 
asthma (296), suggesting that oxidative stress may contribute to steroid 
resistance.  In support of this hypothesis, the level in exhaled breath condensate 
of one marker of oxidative stress, 8-isoprostane, was unaltered by treatment 
with ICS in children with asthma (297).  Another possible mechanism of 
reduced steroid responsiveness in association with cigarette smoking is through 
alterations in the levels and activity of HDACs.  In smokers with COPD, a 
disease characterised by little clinical response to GC, HDAC2 expression and 
activity is reduced (298) and restoration of HDAC2 expression by transfection 
into alveolar macrophages from BALF of COPD patients restored GC function 
(299). 
 
New biological therapies, such as the anti-IgE antibody omalizumab, anti IL-5 
therapy and anti-TNFα therapy may be of benefit for some patients with 
steroid dependent or CR asthma, however they have significant limitations.  
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Omalizumab is only of benefit for a very small subgroup of patients with a 
highly atopic phenotype (261); anti-IL-5 similarly has only shown benefit in 
particular subgroups and is currently only available within the context of 
clinical trials (66), whilst trials of anti-TNFα therapy have had variable results.  
Early trials with the synthetic soluble TNF-α receptor etanercept showed 
promising results, with significant improvements in lung function and 
symptom scores (215, 216).  However, a more recent trial showed less 
dramatic results, with a small improvement in Asthma Control Questionnaire 
score but no significant difference between treatment and placebo groups in 
Asthma Quality of Life Questionnaire Score or measures of lung function 
(300).  Furthermore, there are significant concerns over the safety profile of 
anti-TNFα treatments (204).  Thus, whilst the mechanisms of CR remain 
unclear, for the small proportion of asthmatic patients with steroid dependent 
or CR asthma, it is clear that new therapeutic options are urgently needed.   
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Figure 1.1  Cross talk between cytokine- and GPCR-mediated pathways.  
Positive regulatory pathways are indicated by arrows, stopped arrows 
represent inhibitory pathways.  Points of interaction between steroids 
(GC) and β-agonists (βag) are shown.  Activating actions of these drugs 
are shown in green, inhibitory effects in red.  Note that steroids have both 
positive and negative effects on gene transcription. They predominantly 
switch off transcription of inflammatory genes, but may also increase 
transcription of a number of anti-inflammatory genes.  Kinases are shown 
in orange, non-kinase signalling proteins in green, transcription factors in 
blue and other transcriptional regulatory proteins in lilac.   
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CHAPTER 2:  AIMS OF THIS THESIS 
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2.1  Aims of this thesis 
In chapter 1 we have summarised current knowledge of the roles of various 
immune cells, structural cells, mediators and cytokines in airway inflammation 
and remodelling in asthma.  We have discussed how, in addition to their 
critical role in bronchoconstriction of the asthmatic airway, airway smooth 
muscle cells play a key part in these inflammatory and remodelling responses.  
Further, that differences beginning to be identified between asthmatic and 
normal ASM are helping to shed light on the causes of airway dysfunction in 
asthma.  We have also discussed current treatment modalities and where these 
fall short for the management of patients with more severe disease.  The 
intense research interest in novel mechanisms of action of existing therapies, 
and how these actions differ between steroid responsive and CR asthmatics, is 
starting to highlight potential new targets for treatment for this subgroup of 
patients whose disease cannot be managed effectively with existing therapies.  
We hypothesised, therefore, that inflammatory mediators and cytokines 
important in driving asthmatic airway inflammation may signal through 
common downstream signalling moieties which may act as promising new 
targets for asthma therapy. 
 
Using primary human airway smooth muscle cells as a model, we therefore set 
out 
 
1) To determine the signalling pathways used by inflammatory mediators 
in asthma, using the important pro-inflammatory mediator ET-1 as an 
example, to upregulate the expression of inflammatory response genes. 
 54 
2) To determine the mechanisms of action of cytokine-mediated 
inflammatory response gene signalling, focusing on mechanisms of 
TNF-α-stimulated eotaxin expression. 
3) To study the mechanisms by which existing asthma therapies, namely 
GC and LABA, affect inflammatory response gene expression. 
4) Through (1), (2) and (3), to identify potential common downstream 
signalling moieties shared by inflammatory mediator-mediated and 
cytokine-mediated pathways that may have therapeutic potential as new 
drug targets for asthma. 
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CHAPTER 3:  MATERIALS AND METHODS 
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3.1  Materials 
Human ET-1, DMEM, penicillin/streptomycin, L-Glutamine, amphotericin B, 
actinomycin D, LY294002, Wortmannin, Salmeterol, DMSO, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (thiazolyl blue [MTT]), 
RedTaq DNA polymerase and NuCLEAR extraction kits were purchased from 
Sigma, Poole, Dorset, UK.  Foetal calf serum was from Seralab, 
Loughborough, Leicestershire, UK.  SB203580, PD98059, SP600125 and 
BQ788 were purchased from Tocris, Bristol, Avon, UK and BQ123 was 
purchased from Merck Biosciences, Nottingham, Nottinghamshire, UK.  
Bosentan was a gift from Dr. Marc Iglarz, Actelion Pharmaceuticals, 
Allschwil, Basel, Switzerland.  Fluticasone was a gift from Dr. Malcolm 
Johnson and 2-[(aminocarbonyl)amino]-5-[4-fluorophenyl]-3-
thiophenecarboxamide (TPCA-1) was a gift from Dr. Rick Williamson, both of 
GlaxoSmithKline, Uxbridge, Middlesex, UK.  MCP-1 and eotaxin ELISA kits 
and recombinant human TNF-α were purchased from R&D Systems, 
Abingdon, Oxfordshire, UK.  RNeasy mini kits were from Qiagen, Crawley, 
West Sussex, UK.  All reagents for reverse transcription and the Dual 
Luciferase Reporter Assay System were purchased from Promega, 
Southampton, Hampshire, UK.  GAPDH, ETA receptor, ETB receptor, MCP-1 
and β2 microblobulin primers were purchased from Sigma Genosys, Haverhill, 
Suffolk, UK.  Primers for ChIP assay, spanning the MCP-1 and eotaxin 
promoters, were purchased from MWG, Ebersberg, Germany.  Excite Real 
Time Mastermix with SYBR Green was from Biogene, Cambridge, 
Cambridgshire, UK.  Nitrocellulose membrane for Western blotting and 
Bradford assay dye reagent were purchased from Bio-Rad, Hemel Hempstead, 
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Hertfordshire, UK.  Anti-p38 MAP kinase and anti-p44/42 MAP kinase 
antibodies (total and phospho-) were from Cell Signaling/New England 
Biolabs, Hitchin, Hertfordshire, UK.  Horseradish peroxidase-conjugated 
secondary antibodies were from DakoCytomation, Ely, Cambridshire, UK.  
ECL Western blotting detection reagent, Hyperfilm-ECL and rainbow coloured 
molecular weight markers were from Amersham, Buckinghamshire, UK.  
Fugene 6 transfection reagent was from Roche Molecular Biochemicals, 
Lewes, East Sussex, UK.  ChIP-IT Express kit was from Active Motif, 
Rixensart, Belgium.  NF-κB p65 and cJun antibodies were from Santa 
Cruz/Insight, Wembley, Middlesex, UK.  Total HDAC activity kit, acetyl 
histone H3, HDAC-1 and HDAC-2 antibodies were from Upstate/Millipore, 
Watford, Hertfordshire, UK.  GAPDH and α-tubulin antibodies were from 
AbD Serotec, Kidlington, Oxford, UK. 
 
3.2  Human airway smooth muscle cell culture 
Human airway smooth muscle cells (HASMC) were prepared as described 
previously (148, 301). Human trachea was obtained from post mortem 
individuals within 12h of death.  Clinical and demographic characteristics of 
the donors (where available) are shown in Table 3.1.  Tissue was transported to 
the laboratory in Dulbecco’s modified Eagle’s medium (DMEM) supplemented 
with 4 mM L-glutamine, 2.5µg/ml amphotericin B, 100 U/ml penicillin, 100 
µg/ml streptomycin and 10% heat inactivated foetal calf serum (FCS, CM+ 
media).  The trachealis smooth muscle was dissected free of epithelium and 
connective tissue under sterile conditions.  Small 2 x 2 mm explants of airway 
smooth muscle were then excised and several explants placed in small petri 
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dishes.  Explants were then bathed in media and incubated in CM+ in 
humidified 5% CO2-95% air at 37°C.  Medium was changed every three days, 
and when cells were approaching confluence, the explants were removed.  
Once confluent, cells were trypsinized with 0.25% trypsin and 0.02% EDTA in 
phosphate buffered saline (PBS), centrifuged, resuspended in CM+ and plated 
out in 75 cm2 flasks.  Once cells had again reached confluence, the passaging 
procedure was repeated and cells resuspended in 90%  FCS + 10% dimethyl 
sulphoxide (DMSO), frozen in liquid nitrogen and stored until required.  The 
cultured tissue was positively identified as HASMC through the combination 
of characteristic light microscopic appearances, positive staining for smooth 
muscle actin, desmin and myosin heavy chain, and negative staining for 
cytokeratin.  Cells were cultured in CM+ in humidified 5% CO2-95% air at 
37°C.  Cells at passage 6-7 were used for all experiments.  The studies were 
approved by the Nottingham Local Research Ethics Committee. 
 
Donor Experimental 
chapter(s) in which 
donor’s cells used 
Age 
(years) 
Sex Notes 
1 4 44 Male No evidence of airway 
disease 
2 4 52 Female No evidence of airway 
disease 
3 4 and 5 No demographic or clinical data available 
4 5 34 Female No clinical data 
available 
5 5 42 Male No clinical data 
available 
 
Table 3.1:  Demographic and, where available, clinical characteristics of 
airway smooth muscle cell donors.  All donor tissue was tracheal in origin. 
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3.3  Time course, concentration response and inhibitor studies 
Confluent HASMC in 24 well plates were growth arrested for 24 h in serum 
free medium and then stimulated at 37°C with  ET-1 or TNF-α (0 – 10 ng/ml) 
for 24 h in concentration response experiments, or with ET-1 or TNF-α (10 
ng/ml) for the times indicated in kinetic experiments.  After incubation for 24 
h, cell culture supernatants were transferred to separate microfuge tubes and 
stored at -20°C until determination of MCP-1 or eotaxin content. 
 
In inhibitor studies, cells were pre-incubated for 30 min with inhibitors or 
vehicle prior to treatment with ET-1 or TNF-α for the times indicated.  The 
vehicle was dimethylsulphoxide (DMSO) for all inhibitors except for 
Bosentan, which was dissolved in water.  Vehicle was added to control wells at 
equivalent concentrations (maximum concentration DMSO 0.2%). 
  
3.4  MCP-1 and eotaxin release 
MCP-1 or eotaxin concentrations in cell culture supernatants were measured by 
enzyme-linked immunosorbant assay (ELISA) using commercially available 
sandwich ELISA kits according to the manufacturers instructions as previously 
described (250).  96 well mirotitre plates were coated with human MCP-1 or 
eotaxin-specific capture antibody at 1 µg/ml (MCP-1) or 2 µg/ml (eotaxin) in 
phosphate buffered saline (PBS) and incubated overnight at room temperature.  
Plates were then washed in 0.05% Tween 20 in PBS and blocked for 1 h at 
room temperature with 1% bovine serum albumin (BSA)/5 % sucrose in PBS, 
to prevent non-specific binding.  An eight point standard curve was generated 
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by serial two-fold dilution of recombinant human MCP-1 or eotaxin (supplied) 
in 1% BSA in PBS, with a top standard of 1000 pg/ml.  Standards or samples 
(100 µl) were then added to wells in duplicate and incubated at room 
temperature for 2h.  Plates were washed again, 100 µl of detection antibody 
(100 ng/ml in 1% BSA) added to each well and samples incubated for 2 h at 
room temperature.  After a further wash, samples were incubated for 20 min at 
room temperature with 100 µl streptavadin-conjugated horseradish peroxidase 
(streptavidin-HRP, supplied), diluted 1:200 in 1% BSA in PBS.  Plates were 
then washed again before addition of 100 µl per well of substrate solution (a 
1:1 mixture of hydrogen peroxide and tetramethylbenzidine) for 20 min at 
room temperature.  The resulting colorimetric reaction was stopped by addition 
of 50 µl per well of 1M sulphuric acid.  The optical density of the wells was 
read at 450 nm with reference wavelength 570 nm.  The concentration of MCP-
1 or eotaxin in samples was determined with reference to the standard curve 
using a computer-generated 4-PL curve fit. 
 
3.5  Reverse transcriptase polymerase chain reaction (RT-PCR) 
3.5.1  RNA extraction 
Confluent, growth arrested HASMC in 24 well plates were treated with serum-
free medium (controls) or serum-free medium containing ET-1 or TNF-α for 
the times indicated.  Three wells of a 24 well plate were used for each 
condition.  Following aspiration of cell culture supernatants, cells were washed 
with phosphate buffered saline (PBS).  PBS was removed and discarded and 
RNA was extracted and purified using the RNEasy mini kit according to the 
manufacturer’s instructions. The concentration of RNA in the purified samples 
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was measured spectrophotometrically.  The absorbance at 260 nm (RNA 
content) and 280 nm (protein content) of a 1:20 dilution of purified RNA was 
measured.  RNA concentration in g/ml was calculated by multiplying A260 by 
20 (dilution factor) x 38 (extinction coefficient for RNA). 
 
3.5.2  Reverse transcription  
An equal quantity of RNA (typically 0.5 – 1 g) from each sample was used 
for the RT step.  RNA was reverse transcribed in a total reaction volume of 25 
l of 1x Moloney murine leukaemia virus (M-MLV) RT buffer, containing 130 
units of M-MLV reverse transcriptase, 26 units of RNase inhibitor, 0.6 g 
oligo(dT)15 primer and a 2 mM concentration of each dNTP.  The reaction was 
incubated at 42°C for 90 min. 
 
3.5.3  Polymerase chain reaction 
Aliquots of RT products were subsequently used for polymerase chain reaction 
(PCR).  RT products (2µl) were amplified in a total reaction volume of 50 l 
1x PCR buffer containing 1.5 mM magnesium chloride, 0.2 mM of each dNTP 
and 0.5 M of both the sense and antisense primers.  Reactions were “hot 
started” by addition of 2.5 units of RedTaq DNA polymerase during the initial 
denaturation step at 95°C.  Amplification was carried out in a PTC 100 thermal 
cycler (MJ Research, Inc).  Primer sequences and amplification time and 
temperature profiles are described under experimental protocols in chapter 4.  
The PCR products were visualized by eletrophoresis on 1% agarose gel in 0.5x 
TBE buffer (89 mM Tris borate, 2 mM EDTA, pH 8.3) after staining with 0.5 
µg/ml ethidium bromide. The ultraviolet (UV)-illuminated gels were 
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photographed, and the densitometry was analyzed using the GeneGenius gel 
documentation and analysis system (Syngene, Cambridge, UK). 
 
3.6  Quantitative real time RT-PCR 
MCP-1, HDAC-1 and HDAC-2 mRNA expression was determined by 
quantitative real time RT-PCR (qRT-PCR).  β-2-microglobulin was used as the 
housekeeping gene (302).  Reverse transcribed cDNA was subjected to real 
time PCR using Excite Real Time Mastermix with SYBR Green and the ABI 
Prism 7700 detection system (Applied Biosystems, Warrington, Cheshire, UK). 
Each reaction consisted of 1x Excite mastermix, SYBR Green (1:60,000 final 
concentration), 40nM of both sense and antisense primers, 1.6µl DNA (or 
dH2O) and H2O to a final volume of 20µl.  Thermal cycler conditions included 
incubation at 95°C for 10 min followed by 40 cycles of 95°C for 15 sec and 
60°C for 1 minute. Integration of the fluorescent SYBR Green into the PCR 
product was monitored after each annealing step. Amplification of one specific 
product was confirmed by melt curve analysis where a single melting peak 
eliminated the possibility of primer-dimer association. For melting curve 
analysis to be performed the products were heated from 60°C to 95°C over 20 
min after the 40 cycles. 
 
To enable the levels of transcripts to be quantified standard curves were 
generated using serial dilutions of HASM cDNA.  Negative controls consisting 
of no template were included and all reactions were set up in triplicate. MCP-1 
or HDAC expression was normalised to the housekeeping gene by dividing the 
MCP-1 or HDAC triplicate value by the mean of the β-2-microglobulin 
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triplicate value.  Primer sequences used for qRT-PCR are described under 
experimental protocols in chapters 4 and 5.   
 
3.7  Western blot analysis 
HASM cells were grown to confluence in 6 well plates and growth arrested for 
24 h.  Two wells were used for each condition.  Immediately before each 
experiment, media was changed to fresh serum-free media and cells were 
treated with ET-1 (10 ng/ml) or TNF-α (10 ng/ml) for the times indicated.  In 
inhibitor studies, cells were pre-incubated with vehicle or inhibitor for 30 min 
prior to stimulation.  The medium was removed, the cells were washed with 
PBS and lysed with 100µl lysis/protein extraction buffer consisting of 25 mM 
Tris·HCl, pH 6.8, 75 mM NaCl, 5 mM EDTA, 0.25% wt/vol sodium 
deoxycholate, 0.05% wt/vol sodium dodecyl sulphate (SDS) and 0.5% vol/vol 
Triton X-100 supplemented with PMSF (0.1 mg/ml), leupeptin (10 µg/ml), and 
aprotinin (25 µg/ml).  The protein content of the extracts was determined by 
Bradford assay (303), and the samples were then diluted 1:4 in Laemmli buffer 
(0.125 M Tris·HCl, 20% vol/vol glycerol, 0.2% wt/vol SDS, 6% vol/vol β-
mercaptoethanol and 0.2% wt/vol bromophenol blue) and boiled for 5 min.  
Denatured proteins (25 µg) were separated by SDS-PAGE using an 8 cm x 8 
cm 7.5% SDS gel and electroblotted onto an Immuno-Blot PVDF membrane in 
Tris buffer (20 mM Tris base, pH 8.3, 192 mM glycine, 20% vol/vol 
methanol). The membrane was blocked overnight in Tris-buffered saline-
Tween (TBS-T, 20 mM Tris-base, pH 7.4, 150 mM NaCl, 0.1% vol/vol Tween 
20) containing 5% wt/vol non-fat dry milk (hereafter referred to as 5% milk). 
After washing in TBS-T, the membrane was then incubated with 1:1000 
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dilution of primary antibody overnight at 4°C in TBS-T containing 5% wt/vol 
BSA (for phosphokinase or total kinase antibodies) or 1 h at room temperature 
in 5% milk (for all other primary antibodies).  Blots were washed with TBS-T 
and incubated with 1:3000 dilution of the appropriate horseradish peroxidase 
(HRP)-conjugated secondary antibody in 5% milk for 1 h at room temperature.  
The blot was washed in TBS-T and staining was achieved with enhanced 
chemiluminescence (ECL) Western blotting detection reagent.  The blot was 
incubated with ECL reagent for 45 sec and finally exposed to high performance 
chemiluminescence film.  The position and molecular weight of the protein of 
interest was validated by reference to rainbow coloured molecular weight 
markers.  Reprobing of the blot for the loading controls GAPDH or α-tubulin 
was carried out by blocking the membrane for 1 h at room temperature in 5% 
milk then following the above steps to detect GAPDH/α-tubulin with anti-
GAPDH antibody (1:20000 dilution) or  anti-α-tubulin antibody (1:5000) in 
5% milk. 
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3.8  Vectors and transient transfections 
3.8.1  Vectors 
MCP-1 promoter/enhancer vectors consisted of the pGL3-basic plasmid vector 
containing either the wild-type human MCP-1 enhancer region (-2802 to -2573 
relative to the translation start codon) or the proximal section of the wild type 
human MCP-1 promoter region (-167 to -1, Figure 3.1) upstream of a 
luciferase reporter gene.  These constructs have previously been described in 
detail (250). 
 
 
Figure 3.1 The human MCP-1 gene is regulated by a distal enhancer 
region containing two nuclear factor kappa B (NF-κB) consensus 
sequences (not shown), and a more complex proximal promoter region.  
The MCP-1 promoter construct used in this study consisted of the 167 bp 
upstream of the translational start codon driving a luciferase reporter 
gene.  Numbers refer to the 5’ nucleotide relative to the translation start 
site.  AP-1: activator protein-1; NF-κB: nuclear factor-κB; Sp1: small 
protein 1; NF-1: nuclear factor-1. 
 
 
The MCP-1 promoter construct deletion series was a gift from Dr. Garzino 
Demo (University of Maryland, USA) (304) and consisted of the PGL2-basic 
plasmid vector containing the 486, 213 or 128 bp upstream of the translational 
start codon driving a luciferase reporter gene (Figure 3.2). 
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Figure 3.2 MCP-1 promoter deletion series.  The MCP-1 promoter 
deletion series consisted of the 486, 213 or 128 bp upstream of the 
translational start codon driving a luciferase reporter gene.  IRIS: 
interferon response inhibitory sequence; GAS: gamma activated site. 
 
 
The NF-κB reporter construct 6NF-κBtkluc was a gift from Dr. Robert Newton 
(University of Calgary, Canada) and contains three tandem repeats of the 
sequence 5'-AGC TTA CAA GGG ACT TTC CGC TGG GGA CTT TCC 
AGG GA-3', which harbours two copies of the NF-κB binding site 
(underlined) upstream of a minimal thymidine kinase promoter driving a 
luciferase reporter gene (305).  The  AP-1 reporter construct pRTU14 was a 
gift from Dr. Arnd Kieser (GSF National Research Centre, Munich, Germany) 
and consists of a luciferase gene under the control of a minimal promoter and 
four TREs (12-O-tetradecanoate-13-acetate responsive element, to which the 
AP-1 transcription factor binds) (306). 
 






	
κ







	


486
213
128
 67 
3.8.2  Transfection protocol 
All transient transfections were conducted using FuGene 6 transfection reagent 
according to the manufacturer’s recommended protocol.  HASMC were seeded 
into 24-well plates at a concentration of 2.5 x 104/ml.  When cells reached 50 
to 60% confluence they were growth arrested for 8 h in serum-free, antibiotic 
free DMEM containing 4 mM L-glutamine. After 8 h, media was changed for 
400 µl of fresh, serum-free, antibiotic-free DMEM.  DNA was complexed with 
FuGene 6 in serum-free, antibiotic free DMEM at a ratio of 1 µg DNA:3 µl 
FuGene 6.  100 µl of DNA:FuGene 6 complex was added to each well of the 
24 well plate to give a final amount of 0.4 µg DNA:1.2 µl FuGene 6 per well.  
After 16 h of incubation, the media was changed and the transfected cells were 
treated with ET-1 (10 ng/ml) or TNF-α at the concentrations indicated, for the 
indicated times.  The cells were then washed with PBS and lysed in 100 µl of 
passive lysis buffer.  Firefly luciferase activity was measured by using the Dual 
Luciferase Reporter Assay System (Promega) with a MicroLumatPlus LB96V 
Automatic Microplate Luminometer (Berthold Technologies, Herts, United 
Kingdom). 
 
3.9  Chromatin immunoprecipitation assay 
ChIP was performed using the ChIP-IT™ Express kit (Active Motif).  HASMC 
in 75cm2 dishes at 80-90% confluence were growth arrested for 24 h and 
incubated with ET-1 (10 ng/ml) or TNF-α (10 ng/ml) for the times indicated.  
Cells were then fixed by incubation for 10 min at room temperature with 1% 
formaldehyde.  The 1% formaldehyde media were removed and the cells 
washed in ice-cold PBS. The reaction was stopped with 0.1 M glycine (5 min 
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room temperature) and the cells washed again with PBS.  The cells were then 
collected in 2 ml PBS supplemented with PMSF and pelleted for 10 min at 
2500 rpm at 4°C.  The cells were re-suspended in lysis buffer (supplied) 
containing PMSF and a protease inhibitor cocktail (PIC) and incubated on ice 
for 30 min.  Cells were centrifuged at 5000 rpm for 10 min at 4°C and the 
pellet re-suspended in shearing buffer (supplied) supplemented with protease 
inhibitors.  Samples were subsequently sonicated (5 x 10 sec pulses with 
incubation on ice between each cycle of sonication) into chromatin fragments 
of an average length of 500 - 800 bp.  The sheared chromatin was centrifuged 
at 13,000 rpm at 4°C for 12 min and the supernatants, containing the sheared 
chromatin, retained.  Ten µl of chromatin from each sample was transferred to 
a fresh microfuge tube and reserved as “input” DNA.  The remaining 
chromatin was aliquoted and incubated with protein G magnetic beads and 
antibody (4 µg) directed against the transcription factor or cofactor of interest 
overnight at 4°C with rotation.  Immunoprecipitated material was washed 3 
times with wash buffer (supplied), and eluted from the magnetic beads by 
incubation in elution buffer (supplied) for 15 min at room temperature with 
rotation.  Cross-links were reversed by addition of reverse cross link buffer 
(supplied) followed by incubation at 65°C for 2.5 h.  Input samples were 
subject to the same incubation to reverse cross links after dilution 1:10 into 
ChIP buffer 2 (supplied) and addition of NaCl to a final concentration of 0.1 
M.  Recovered material was treated with proteinase K and incubated at 37°C 
for 60 min to digest the proteins.  Input samples were subject to an additional 
purification step prior to PCR analysis.  Input samples were treated with 
RNAse A and incubated at 37°C for 30 min prior to phenol chloroform 
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extraction.  The recovered DNA was quantified by PCR as described in section 
3.5.3, using the specific primers spanning the regulatory region of the human 
MCP-1 or eotaxin promoters and the following time and temperature profiles:  
initial denaturation at 94°C for 3 min, followed by 30 cycles of denaturation at 
94°C for 20 sec, primer annealing at 59°C for 30 sec, primer extension at 72°C 
for 30 sec.   
 
3.10  Cell viability (MTT) assay 
The toxicity of inhibitors and the vehicle DMSO to HASMC was determined 
by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (thiazolyl 
blue [MTT], Sigma).  After incubation with the chemicals for the indicated 
times, the cell culture supernatants were aspirated and 250 µl of 1 mg/ml MTT 
in serum-free medium was added to each well of a 24 well plate and incubated 
for 20 min at 37°C.  The MTT medium was removed and 250 µl of DMSO was 
added to solubilize the blue-coloured tetrazolium.  Optical densities were read 
at 550 nm in a microplate reader.  Viability was compared to that of control 
cells, with viability of controls defined as 100%. 
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CHAPTER 4:  REGULATION OF MONOCYTE CHEMOTACTIC PROTEIN-1 
EXPRESSION BY ENDOTHELIN-1 
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4.1  Introduction 
As described in chapter 1, asthma is an inflammatory disease of the airways.  
Resolution of inflammation normally results in restoration of normal tissue 
structure and function.  In chronic asthma, these processes become disordered, 
leading to airway remodelling, manifest as an increase in ASM mass, mucous 
gland hyperplasia, an increase and alteration in extracellular matrix (ECM) and 
subepithelial fibrosis (126). The increased thickness of the ASM layer is a key 
feature of the remodelled asthmatic airway.  This is highly significant, since in 
addition to their contractile properties, ASM cells are a rich source of 
cytokines, mediators, chemokines, growth factors and matrix modifying 
enzymes that contribute to airway inflammation and remodelling. 
 
Inflammatory response genes can be switched on by Th-1 (307) or Th-2 (308) 
cytokines or inflammatory mediators acting at 7 transmembrane GPCRs (309).  
Activation of gene expression by GPCRs provides an important means of local 
production of cytokines and growth factors which contribute to inflammation 
and remodelling (309).  As we discussed in chapter 1, in contrast to gene 
expression events mediated by cytokines, the nuclear signalling cascades used 
by GPCRs have not been well characterised.  Human ASM cells (HASMC) are 
a useful model system to study GPCR signalling in primary cells as they 
express the GPCRs for many important inflammatory mediators (178, 310). 
 
The Knox lab have previously shown that the inflammatory mediator BK can 
actively signal to the nucleus to mediate gene transcription events using 
complex prostanoid dependent signalling pathways involving AP-1, NF-κB 
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and C/EBP (311, 312).  These signals are transduced by the Gαq-coupled B2 
BK receptor.  It is not clear whether these nuclear signalling pathways are 
unique to BK or shared by other Gαq-linked GPCRs.  Endothelin-1 (ET-1) is a 
21 amino acid vasoactive and pro-inflammatory peptide that acts at Gαq-
coupled ETA and ETB receptors.  As described in chapter 1, there is extensive 
evidence implicating ET-1 in the pathogenesis of asthma.  There has been a 
wealth of studies of the effects of ET-1 on ASM contraction but, despite animal 
studies implicating ET-1 in airway inflammation, there have been very few 
previous studies of ET-1’s effects on release of inflammatory cytokines and 
mediators from ASM.  ET-1 has been shown to increase the release of the 
chemokines IL-8 and MCP-1 from several other cell types in vitro (241, 313, 
314) and has been implicated in induction of chemokine release in vivo (241, 
315, 316). 
 
The ETA and ETB receptors activate calcium and inositol phosphate second 
messenger pathways (317-319).  ET-1 can also activate the MAPK family of 
signalling proteins. For example, ET-1 activates ERK-2 and JNK in rat tracheal 
smooth muscle cells (319, 320).  Similarly, ET-1 induces the MEK/ERK 
pathway in human lung fibroblasts (191), and the ERK 1/2, p46 and p54 JNKs 
and p38 MAPKs in cardiac myocytes (192).  However, there have been few 
studies of nuclear signalling by ET-1 and, furthermore, the transcriptional and 
post-transcriptional regulation of chemokine expression by ET-1 has not been 
studied. 
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As described in chapter 1, MCP-1 is a chemokine of the CC subgroup which is 
chemotactic for monocytes (236, 237) and T-lymphocytes (238, 239) and is, 
like ET-1, implicated in the pathophysiology of asthma through multiple lines 
of evidence.  The Knox group and others have shown that HASMC express 
MCP-1 and that levels of expression are upregulated by cytokines (242, 249, 
250).  However, there have been few studies in ASM of the effects on MCP-1 
expression by asthma mediators acting at GPCRs, although it is known that 
bradykinin induces MCP-1 secretion from human lung fibroblasts (321).  The 
aim of the experiments described in this chapter was to determine the 
mechanisms used by ET-1 to induce MCP-1 expression.  We used a variety of 
molecular and pharmacological tools to characterise the signalling pathways 
involved.  Specifically we tested the hypotheses that: 
1. ET-1 stimulates MCP-1 release from HASMC. 
2. This occurs through a transcriptional mechanism. 
3. The downstream signalling pathways are MAP kinase dependent. 
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4.2  Experimental protocols 
HASMC were grown in 6 well plates (Western blotting experiments), 75cm2 
flasks (ChIP assay) or 24 well plates (all other experiments) as described in 
chapter 3.  Cells were growth arrested for 24 h prior to each experiment.  The 
principle findings of this study were confirmed in tissue from three different 
donors.  Subsequent mechanistic studies were performed on cells from one 
donor.   
 
4.2.1 MCP-1 release from HASMC 
Human MCP-1 release from HASMC was measured using a commercially 
available ELISA kit (R&D) as described in chapter 3. 
 
4.2.2 Determination of ET receptor mRNA expression by polymerase chain 
reaction 
RNA extraction, reverse transcription and PCR were carried out as described in 
chapter 3.  The primer sequences used were as follows:  GAPDH sense, 5'-
CCA CCC ATG GCA AAT TCC ATG GCA-3'; GAPDH antisense, 5'-TCT 
AGA CGG CAG GTC AGG TCC ACC-3'; ETA receptor sense, 5’-TGG CCT 
TTT GAT CAC AAT GAC TTT-3’; ETA receptor antisense, 5’-TTT GAT 
GTG GCA TTG AGC ATA CAG GTT-3’; ETB receptor sense, 5’-ACT GGC 
CAT TTG GAG CTG AGA TGT-3’; ETB receptor antisense, 5’-CTG CAT 
GCC ACT TTT CTT TCT CAA-3’ (182, 322).  PCR was carried out using the 
following temperature and time profiles.  GAPDH:  initial denaturation at 95°C 
for 3 min, followed by 30 cycles of denaturation at 95°C for 30 sec, primer 
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annealing at 60°C for 30 sec, primer extension at 72°C for 30 sec.  A final 
chain extension was carried out at 72°C for 10 min.  ET receptors:  initial 
denaturation at 94°C for 1 min followed by 35 cycles of denaturation at 94°C 
for 1 min, primer annealing at 54°C for 1 min, primer extension at 72°C for 3 
min.  Final chain extension was carried out at 72°C for 10 min.   
 
4.2.3 Determination of MCP-1 mRNA expression by real time polymerase 
chain reaction 
Real time PCR was carried out as described in chapter 3.  Primer sequences 
used were as follows:  MCP-1 sense, 5- GAT CTC AGT GCA GAG GCT CG -
3’; MCP-1 antisense, 5’- TGC TTG TCC AGG TGG TCC AT -3’ (250); β2 
microglubulin sense, 5’- GAG TAT GCC TGC CGT GTG-3’; β2 
microglobulin antisense, 5’- AAT CCA AAT GCG GCA TCT-3’ (302); 
 
4.2.4 Chromatin immunoprecipitation assay 
ChIP assay was performed as described in chapter 3.  Primer sequences used to 
amplify the immunoprecipitated products by PCR were as follows:  MCP-1 
promoter sense: 5’-CCC ATT TGC TCA TTT GGT CTC AGC-3’; MCP-1 
promoter antisense: 5’-GCT GCT GTC TCT GCC TCT TAT TGA-3’ (243).   
 
4.2.5 Data Analysis 
MCP-1 protein or mRNA or luciferase levels were expressed as the means of 
the individual technical replicates for that experiment.  The experiments were 
repeated at least twice, and the results shown represent group means +/- SE.  
Absolute MCP-1 levels are presented for the initial concentration response and 
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time course experiments.  In subsequent mechanistic studies, the data are 
expressed as fold increase or percentage of control.  The number of 
independent experiments and technical replicates from which the data are 
derived is also indicated in the figure legends.  Analysis of variance (ANOVA) 
of the raw data was used to determine statistically significant differences, using 
the statistical software package SPSS version 14.0.  In time course 
experiments, the terms of the ANOVA included experiment, time and ET-1.  
Overall p-values for the effect of time and ET-1 are presented.  Time 
dependence of the effect of ET-1 was determined by fitting an interaction 
between ET-1 and time. In concentration response experiments, the terms of 
the ANOVA included experiment and concentration.  Overall p values for the 
effect of ET-1 or inhibitor are presented.  Comparisons between individual 
concentrations of ET-1 and control, or inhibitor compared to ET-1-stimulated 
cells, were assessed using Dunnet’s post-hoc correction for multiple 
comparisons.  A p value of <0.05 was regarded as statistically significant. 
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4.3  Results 
4.3.1 ET-1 stimulates the release of MCP-1 from cultured HASMC 
We first studied the effect of ET-1 on the release of MCP-1 from HASMC.  
Sub-confluent, growth arrested cultured HASMC were treated for 24 h with 
increasing concentrations of ET-1 up to 10 ng/ml.  ET-1 stimulated MCP-1 
release in a concentration dependent manner (Figure 4.1).  In other experiments 
where higher concentrations of ET-1 were used, no further increase in effect 
was observed (data not shown). Ten ng/ml of ET-1 was therefore used in all 
subsequent experiments.  HASMC were next treated with 10 ng/ml of ET-1 for 
0, 1, 2, 4, 8, 16 and 24 h.  ET-1 caused a time dependent increase in MCP-1 
release (Figure 4.2). 
 
 
 
Figure 4.1 Concentration response of ET-1-stimulated MCP-1 
production by HASMC.  Cells were treated for 24 h with ET-1 at the 
concentrations indicated.  ET-1 significantly increased MCP-1 release 
(p<0.001).  ***P<0.001 compared with unstimulated cells.  Each bar 
represents group mean (SE) derived from 13 replicates in 4 independent 
experiments (n=3 different primary donors). 
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Figure 4.2 Time course of ET-1-stimulated MCP-1 production by 
HASMC.  Cells were treated with ET-1 (10 ng/ml) for the indicated times.  
ET-1 significantly increased MCP-1 release from HASMC in a time-
dependent manner (ET-1 vs control: p<0.001.  Interaction between ET-1 
and time: p<0.001).  Each bar represents group mean (SE) derived from 
18 replicates in 7 independent experiments (n=3 different primary 
donors). 
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4.3.2  HASMC express endothelin A and endothelin B receptor mRNA 
Two endothelin receptors have been cloned and sequenced, the ETA and ETB 
receptors. To determine whether HASMC expressed these receptors we used 
RT-PCR to look at their RNA.  RT- PCR demonstrated the presence of mRNA 
for both receptors in HASMC (Figure 4.3). 
 
 
 
 
 
Figure 4.3 ETA and ETB receptor mRNA is expressed in HASMC.  
Representative gel from one of 3 independent experiments. 
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4.3.3 Effects of ET-1 on MCP-1 release are mediated by ETA and ETB 
receptors 
We next performed pharmacological studies to explore the relative 
contributions of the two receptor subtypes to ET-1-mediated MCP-1 
expression.  The dual-selective ET receptor antagonist bosentan and the 
selective ETA and ETB receptor antagonists, BQ123 and BQ788 respectively, 
inhibited ET-1-stimulated MCP-1 production in a concentration-dependent 
manner (Figures 4.4 to 4.6).  Both antagonists inhibited ET-1-stimulated 
MCP-1 production at concentrations equivalent to and ten-fold higher than 
their respective pA2 values (6.9 - 7.4 and 6.9 for BQ123 and BQ788 
respectively (323)).  The antagonist concentrations were chosen to be selective 
for the relevant receptor, as both inhibitors are at least 3 orders of magnitude 
more selective for their respective receptors (324, 325).  These data suggest 
that both ETA and ETB receptors are involved in this response.  An additional 
effect was observed when BQ123 and BQ788 were used in combination at a 
submaximal concentration (Figure 4.7) but this was of borderline statistical 
significance (p=0.05). 
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Figure 4.4 The dual selective ET receptor antagonist bosentan 
concentration-dependently inhibited ET-1-stimulated MCP-1 production 
(p<0.001).  ***P<0.001 compared with ET-1-stimulated cells.  Each bar 
represents group mean (SE) derived from 11 replicates in 3 independent 
experiments. 
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Figure 4.5 The selective ETA receptor antagonist BQ123 concentration-
dependently inhibited ET-1 stimulated MCP-1 production (p<0.001).  
***P<0.001 compared with ET-1-stimulated cells. 
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Figure 4.6 The selective ETB receptor antagonist BQ788 concentration-
dependently inhibited ET-1 stimulated MCP-1 production (p<0.001).  
*P=0.03; ***p<0.001 compared with ET-1-stimulated cells. 
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Figure 4.7 BQ123, BQ788 and both inhibitors in combination (10-7 M) 
significantly inhibited ET-1-stimulated MCP-1 production (p<0.001).  P 
for interaction = 0.053. 
 
Figures 4.5 – 4.7:  each bar represents group mean (SE) derived from 6 
replicates in 2 independent experiments. 
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4.3.4  Effects of ET-1 on MCP-1 release are mediated by p44/p42 and  p38 
MAP kinases but not by JNK or PI3 kinase 
MAP kinases are involved in multiple inflammatory pathways, including 
airway inflammation (326) and, furthermore, it is known that ET-1 can activate 
MAP kinases in ASM and other biological systems (191, 319, 320, 327).  We 
therefore hypothesised that ET-1 may stimulate MCP-1 release through MAP 
kinase dependent pathways.  PD98059 (20 µM), a selective inhibitor of MEK, 
immediately upstream of p44/p42 MAPK, or ERK (328, 329), inhibited ET-1 
stimulated MCP-1 production (Figure 4.8) suggesting a role for p44/p42 MAP 
kinase.  Consistent with this, Western blotting demonstrated a time dependent 
increase in phosphorylation of p44/p42 MAP kinase following stimulation with 
ET-1 (Figure 4.9). 
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Figure 4.8 Effect of PD98059 on ET-1-stimulated MCP-1 production.  
PD98059 (20 µM) inhibited ET-1-stimulated MCP-1 production.  
***p<0.001 compared with cells treated with ET-1 alone.  Each bar 
represents group mean (SE) derived from 11 replicates in 3 independent 
experiments. 
 
 
 
Figure 4.9 Western blot showing time-dependent phosphorylation of 
p44/p42 MAPK by ET-1.  An increase in phospho-p44/p42 MAPK is seen 
at 5 minutes and is sustained until 30 minutes.  Representative blot from 
one of 4 independent experiments. 
0
100
200
300
400
500
***
ET-1
Control
M
C
P-
1 
(%
 
o
f c
o
n
tr
o
l)
PD98059
20 µM
Control ET-1
Phospho p44/p42
Total p44/p42
Time (min) 0 5 10 15 30 60 120 0 5 10 15 30 60 120
 87 
 
The p38 MAP kinase inhibitor SB203580 (20 µM) also inhibited ET-1-
stimulated MCP-1 production (Figure 4.10) (330).  Furthermore, ET-1 caused 
an increase in phosphorylation of p38 on Western blotting (Figure 4.11). 
 
 
 
Figure 4.10 Effect of SB203580 on ET-1-stimulated MCP-1 production.  
SB203580 (20 µM) inhibited ET-1-stimulated MCP-1 production.  
***P<0.001 compared with cells treated with ET-1 alone.   Each bar 
represents mean (SE) of 16 replicates in 2 independent experiments. 
 
 
 
 
Figure 4.11 Western blot showing time-dependent phosphorylation of 
p38 MAPK by ET-1.  An increase in phospho-p38 MAPK is seen at 5 
minutes and is sustained until 30 minutes.  Representative blot from one of 
3 independent experiments. 
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In contrast to our observations with PD98059 and SB203580, the selective 
JNK inhibitor SP600125 (10 µM) (331) and the PI3 kinase inhibitors 
Wortmannin (100 nM) and LY294002 (1 µM) (332, 333) had no effect on ET-
1-stimulated MCP-1 production (Figures 4.12 and 4.13). 
 
 
 
 
 
Figure 4.12 The JNK inhibitor SP600125 (10µM) had no effect on ET-1-
stimulated MCP-1 production.  Each bar represents group mean (SE) 
derived from 10 replicates in 3 independent experiments. 
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Figure 4.13 Effect of the PI 3 kinase inhibitors wortmannin and 
LY294002 on ET-1-stimulated MCP-1 production.  Wortmannin (10-7 M) 
and LY294002 (10-6 M) had no effect on ET-1-stimulated MCP-1 
production.  Each bar represents group mean (SE) derived from 8 
replicates in 2 independent experiments. 
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4.3.5  ET-1 increases MCP-1 mRNA levels 
We next tested the hypothesis that the regulation of MCP-1 expression by ET-1 
occurs at a transcriptional level.  We used qRT-PCR to determine the levels of 
MCP-1 mRNA following treatment of HASMC with ET-1 (10 ng/ml).  MCP-1 
mRNA levels were normalised to the house keeping gene β2 microblogulin.  
ET-1 significantly increased MCP-1 mRNA levels relative to control 
(unstimulated) cells (Figure 4.14).  The increase was detectable at 2 h, and was 
sustained throughout the 24 hour period studied. 
 
 
 
Figure 4.14 ET-1 increased expression of MCP-1 mRNA measured by 
qRT-PCR (p<0.001 compared to control cells).  The effect was time 
dependent (p for interaction between ET-1 and time = 0.003).  MCP-1 
mRNA was normalised to the housekeeping gene β2 microglobulin.  Each 
bar represents group mean (SE) derived from 12 replicates in 4 
independent experiments. 
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4.3.6  ET-1 does not affect MCP-1 mRNA stability 
We performed mRNA stability studies with the transcription inhibitor 
actinomycin D (Act D) to determine whether ET-1’s effects on MCP-1 mRNA 
levels were due to stabilisation of the MCP-1 mRNA.  MCP-1 mRNA is 
constitutively expressed in HASMC.  Cells were incubated for 0 to 24 h with 1 
µg/ml of Act D alone (which blocks the production of new transcripts), or Act 
D and ET-1 in combination.  ET-1 had no effect on the rate of decay of MCP-1 
transcripts, indicating that ET-1 was not acting to stabilise MCP-1 mRNA 
(Figure 4.15). 
 
 
 
Figure 4.15 Effect of ET-1 on MCP-1 mRNA stability.  ET-1 treatment 
had no effect on the rate of decay of MCP-1 transcripts.  Each point 
represents group mean (SE) derived from 6 replicates in 3 independent 
experiments. 
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4.3.7  ET-1 increases MCP-1 promoter activity 
Next, vectors encoding the wild type MCP-1 promoter or enhancer regions 
upstream of a luciferase reporter gene were transiently transfected into 
HASMC.  Consistent with the qRT-PCR results, ET-1 caused a 2.2-fold 
increase in MCP-1 promoter-driven luciferase reporter gene expression at 6 h.  
This effect was still detectable at 16 h as a 1.7-fold increase (Figure 4.16).  
There was a trend towards a smaller and later stimulation of MCP-1 enhancer-
driven reporter gene expression, with a 1.7-fold increase detected following 16 
h incubation with ET-1 (Figure 4.17), although this did not reach statistical 
significance (p=0.1). 
 
 
 
Figure 4.16 Effect of ET-1 on MCP-1 promoter activity.  ET-1 
stimulated MCP-1 promoter-driven luciferase activity (p=0.03 compared 
to controls).  Each bar represents group mean (SE) derived from 18 
replicates in 3 independent experiments. 
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Figure 4.17 Effect of ET-1 on MCP-1 enhancer activity.  Although there 
was a trend towards an effect of ET-1 on MCP-1 enhancer-driven 
luciferase activity, this was not statistically significant (p=0.106 compared 
to controls).  Each bar represents group mean (SE) derived from 16-26 
replicates in 3-6 independent experiments. 
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4.3.8  Effects of ET-1 on the MCP-1 promoter map to a region between 213 
and 128 base pairs upstream of the translational start codon 
In order to determine which region of the MCP-1 promoter was responsible for 
ET-1’s effects, HASMC were transiently transfected with constructs 
expressing serial deletions of the human MCP-1 promoter, consisting of the 
486, 213 or 128 bp upstream of the translational start codon.  Cells were 
stimulated with ET-1 for 6 h, since maximal transactivation of the wild-type 
promoter was observed at this time.  ET-1 significantly up-regulated activity of 
the 486 and 213 constructs but had no effect on activity of the 128 construct, 
suggesting that the region between 213 and 128 bp upstream of the 
translational start codon is required for the effects of ET-1 on MCP-1 
transcriptional activation (Figure 4.18). 
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Figure 4.18 HASMC were transiently transfected with serially deleted 
MCP-1 promoter constructs consisting of the 486, 213 or 128 bp upstream 
of the translational start codon and stimulated with ET-1 for 6 h.  ET-1 
stimulated luciferase activity driven by the 486 and 213 constructs but had 
no effect on the 128 construct.  **p=0.008; ***p<0.001.  Each bar 
represents group mean (SE) derived from 18 replicates in 3 independent 
experiments.  IRIS = interferon regulated inhibitory sequence; GAS = 
gamma activated site; AP-1 = activator protein-1; NF-κB = nuclear factor-
κB; Sp1 = small protein-1;  NF-1 = nuclear factor 1. 
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4.3.9  ET-1 stimulates activity of an NF-κB and an AP-1 reporter construct 
The region between 128 and 213 bp upstream of the MCP-1 translational start 
codon contains consensus sequences for the transcription factors NF-κB and 
AP-1.  To confirm that ET-1 can activate these transcription factors in 
HASMC, we transiently transfected HASMC with NF-κB and AP-1 reporter 
constructs and stimulated with ET-1 for 6h.  ET-1 caused a 1.7-fold increase in 
luciferase activity of the NF-κB construct (Figure 4.19) and a 1.6-fold increase 
in activity of the AP-1 construct (Figure 4.20). 
 
 
 
Figure 4.19 Effect of ET-1 on NF-κB reporter-driven luciferase activity 
following treatment with ET-1 for 6 h.  *P=0.03 compared with control.  
Each bar represents group mean (SE) of 18 replicates in 3 independent 
experiments. 
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Figure 4.20 Effect of ET-1 on AP-1 reporter-driven luciferase activity 
following treatment with ET-1 for 6 h.  *P=0.03 compared with control.  
Each bar represents group mean (SE) of 12 replicates in 2 independent 
experiments. 
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4.3.10  JNK inhibition has no effect on ET-1-stimulated MCP-1 promoter 
activity 
Since ET-1 activated both the 128 MCP-1 promoter construct (containing two 
AP-1 consensus sequences) and the AP-1 reporter construct, we hypothesised 
that inhibition of JNK, an upstream activator of AP-1, would inhibit ET-1-
stimulated MCP-1 promoter activity.  Interestingly, however, the JNK inhibitor 
SP600125 (10M) had no effect on ET-1-stimulated MCP-1 promoter activity 
(Figure 4.21). 
 
 
 
Figure 4.21 Effect of SP600125 on ET-1-stimulated MCP-1 promoter 
activity.  HASMC transiently transfected with the wild-type MCP-1 
promoter construct were stimulated with ET-1 for 6 h in the absence or 
presence of the JNK inhibitor SP600125.  SP600125 had no effect on ET-1-
stimulated MCP-1 promoter activity.  **p=0.009 compared with controls.  
Each bar represents group mean (SE) derived from 12 replicates in 2 
independent experiments. 
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4.3.11  Inhibitor of κB kinase-2 (IKK-2) blockade inhibits ET-1-stimulated 
MCP-1 release 
Our findings with the transiently transfected MCP-1 promoter and NF-κB 
reporter constructs suggested that NF-κB was involved in ET-1-stimulated 
MCP-1 release.  We next studied the effect of the inhibitor TPCA-1 (which 
blocks IKK-2, thereby inhibiting the NF-κB activation pathway) on ET-1-
stimulated MCP-1 release.  TPCA-1 concentration-dependently inhibited ET-1-
stimulated MCP-1 production with a –log IC50 of 6.2 +/- 0.1 (Figure 4.22), 
further supporting the hypothesis that NF-κB is involved in ET-1-stimulated 
MCP-1 production. 
 
 
 
Figure 4.22 Cells were pre-incubated with the IKK-2 inhibitor TPCA-1 
for 30 min prior to 24 h stimulation with ET-1.  TPCA-1 concentration-
dependently inhibited ET-1-stimulated MCP-1 production (4 parameter 
logistic regression).  Each point represents group mean (SE) derived from 
12 replicates in 4 independent experiments. 
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4.3.12  ET-1 promotes in-vivo binding of NF-κB p65 subunit and AP-1 cJun 
subunit to the MCP-1 promoter 
To confirm whether NF-κB, AP-1, or both were involved in ET-1’s effects at 
the MCP-1 promoter, we studied the in vivo binding of these transcription 
factors to the MCP-1 promoter by ChIP assay.  We found that ET-1 stimulated 
binding of both p65 and cJun to the MCP-1 promoter, suggesting that both 
transcription factors are involved (Figures 4.23 and 4.24).  We observed a 1.5-
fold increase in p65 binding to the MCP-1 promoter at 1 h, with a return to 
basal levels by 1.5 h.  A similar transient rise in cJun binding to the MCP-1 
promoter was observed, with a 2.2-fold increase in cJun binding seen at 1 h 
that returned to basal levels by 2.5 h. 
 
 
 
 
Figure 4.23 ChIP assay, with accompanying densitometry, showing 
effect of ET-1 on in vivo binding of NF-κB p65 subunit to the MCP-1 
promoter.  ET-1 promoted in vivo binding of p65 to the MCP-1 promoter.  
The density of the immunoprecipitated band (IP) was normalised to that 
of the input control at the same time point, and expressed as fold increase 
over time zero.  Representative gel from one of two independent 
experiments.   NAC = no antibody control. 
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Figure 4.24 ChIP assay, with accompanying densitometry, showing 
effect of ET-1 on in vivo binding of AP-1 cJun subunit to the MCP-1 
promoter.  ET-1 promoted in vivo binding of cJun to the MCP-1 promoter.  
The density of the immunoprecipitated band (IP) was normalised to that 
of the input control at the same time point, and expressed as fold increase 
over time zero. Representative gel from one of two independent 
experiments.  NAC = no antibody control. 
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4.3.13  PD98059 and SB203580 inhibit ET-1-stimulated binding of p65 and 
cJun to the MCP-1 promoter 
We next performed ChIP assay to study the effects of the MEK inhibitor 
PD98059 (20 µM) and the p38 MAPK inhibitor SB203580 (20 µM) on ET-1-
stimulated binding of p65 and cJun to the MCP-1 promoter.  PD98059 and 
SB203580 inhibited p65 and cJun binding to the MCP-1 promoter (Figure 
4.25). 
 
 
 
Figure 4.25 ET-1-stimulated binding of p65 and cJun to the MCP-1 
promoter at 1h was inhibited by PD98059 (PD, 20 µM) and SB203580 (SB, 
20 µM).  The density of the immunoprecipitated band (IP) was normalised 
to that of the input control of the same condition, and expressed as fold 
increase over unstimulated cells.  Representative gels, with accompanying 
densitometry, from one of two independent experiments.  NAC = no 
antibody control. 
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4.3.14  Cell viability 
Cell viability with all chemicals/inhibitors used in this study was greater than 
90 % of that of control cells as determined by MTT assay (see Appendix). 
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4.4  Discussion 
The major finding of this study is that ET-1 induces MCP-1 expression in 
HASMC and that this occurs through a transcriptional mechanism involving 
activation of the MCP-1 promoter region.  Furthermore, the regulation of 
MCP-1 by ET-1 involves ETA and ETB receptors and both p44/p42 MAPK and 
p38 MAPK dependent pathways, but not JNK or PI3 kinase dependent 
pathways. 
 
We found that ET-1 increased MCP-1 production in a concentration and time 
dependent manner (Figures 4.1 and 4.2).  MCP-1 is released from HASMC 
constitutively, thus even under unstimulated conditions (control cells), MCP-1 
accumulates in the culture medium over time.  However, there is a clear 
increase in MCP-1 release from the ET-1 stimulated cells.  Of note, a previous 
study in HASMC did not show induction of MCP-1 in response to ET-1 (242).  
However, the concentration of ET-1 used in that study was 1 µM, or 2492 
ng/ml, some 250-fold higher than the concentration used in our study.  It may 
be that ET-1’s effects are biphasic, with a loss of effect at this higher 
concentration.  There are isolated reports of ET-1 increasing MCP-1 
production in endothelial and mesangial cells (241, 334), but none from 
HASMC.  Furthermore, the mechanisms used by ET-1 to up-regulate MCP-1 
expression have not been studied in any biological system. 
 
We next determined the endothelin receptor(s) responsible for its effects.  Two 
endothelin receptors have been identified and cloned, ETA and ETB receptors, 
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both of which are expressed by HASMC (335, 336).  We confirmed the 
presence of mRNA for both receptors in HASMC by RT-PCR (Figure 4.3).  
Our studies with antagonists of differing ET-receptor specificity indicated that 
both receptor subtypes are involved in ET-1 stimulated MCP-1 release (Figures 
4.4 to 4.6 respectively).  Both antagonists inhibited ET-1-stimulated MCP-1 
production at concentrations equivalent to and ten-fold higher than their 
respective pA2 values (6.9 - 7.4 and 6.9 for BQ123 and BQ788 respectively 
(323)).  The antagonist concentrations were chosen to be selective for the 
relevant receptor, as both inhibitors are at least 3 orders of magnitude more 
selective for their respective receptors (324, 325). Our observations using the 
ETA and ETB receptor antagonists are interesting as they contrast with ET-1-
potentiated HASMC proliferation, which appears to be mediated solely by ETA 
receptors (197) and ET-1-mediated HASM contraction, which is 
predominantly ETB mediated (335, 337) (although one study suggested that 
both receptors contribute (336)). 
 
Inhibition of the effects of ET-1 by each of the selective ET receptor 
antagonists strongly implies the presence of both receptor subtypes at the 
protein level.  However, our findings would be strengthened by confirming 
receptor expression at the protein level.  Potential techniques that could be used 
to demonstrate the presence of ETA and ETB receptors include flow cytometry, 
immunofluorescent labelling coupled with confocal microscopy, or Western 
blotting.  Although, as discussed above, the ET receptor antagonists BQ123 
and BQ788 should be selective for their respective targets at the concentrations 
used in this study, it is possible that the observed effects could be brought 
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about through non-selective effects on the opposite receptor.  Demonstrating 
the presence of both receptors at the protein level would support the inference 
that both receptor subtypes are involved in ET-1-stimulated MCP-1 expression. 
 
To further probe the signalling pathways involved we turned our attention to 
kinase cascades. Studies using kinase inhibitors suggested that ET-1-stimulated 
MCP-1 production by HASMC involved p44/42 and p38 MAP kinases, but not 
JNK (Figures 4.8, 4.10 and 4.12 respectively) (328-331).  Consistent with the 
inhibitor studies, ET-1 was shown to activate p44/p42 and p38 MAP kinases 
by Western blotting (Figures 4.9 and 4.11 respectively). 
 
ET-1 activates MAP kinases in a number of systems (319, 320, 327, 338).  
P44/p42 MAP kinase is known to be activated by ET-1 in ASM from other 
species and has been implicated in ET-1-mediated proliferative responses (319, 
320, 339, 340).  Furthermore, p44/p42 MAPK and p38 MAPK are involved in 
IL-1β-stimulated MCP-1 production in HASMC (341).  This is interesting as it 
suggests that cross talk could occur between cytokine- and GPCR-mediated 
pathways of chemokine expression.  MAP kinases are involved in multiple 
inflammatory pathways (342) and it has been shown that MAPK inhibitors can 
attenuate the inflammatory disease process in animal models of rheumatoid 
arthritis (343, 344).  Interestingly, ET-1 induces expression by human lung 
fibroblasts of connective tissue growth factor, an important profibrotic protein 
that induces collagen synthesis, via a p44/p42 MAPK dependent pathway, 
suggesting that ET-1 may be involved in both the inflammatory and 
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remodelling components of asthmatic disease and that both components 
involve p44/p42 MAPK. 
 
The ET-1 receptors, ETA and ETB, are seven transmembrane GPCRs which 
couple to Gαq and activate calcium and inositol phosphate second messenger 
pathways (317-319).  There is also some experimental evidence that Gαq can 
activate PI3 kinase (192, 345), although this pathway is not well characterised.  
Pharmacological studies using wortmannin and LY294002 implicated PI3 
kinase in the development of an enhanced contractile phenotype of pulmonary 
fibroblasts by ET-1(338).  In contrast, mitogenic signalling in response to ET-1 
in bovine ASM appeared to be independent of PI3 kinase (346).  We found that 
the PI3 kinase inhibitors wortmannin and LY294002 had no effect on ET-1-
stimulated MCP-1 production, suggesting that ET-1’s effects are not mediated 
by PI3 kinase (Figure 4.13).  The concentrations of these inhibitors were 
selected to be equal to or higher than their published IC50 values (332, 333).  
 
We found that MCP-1 mRNA is expressed by HASMC under resting 
conditions, and that ET-1 increased MCP-1 mRNA (Figure 4.14).  Studies of 
MCP-1 mRNA stability confirmed that this was not an effect on stabilisation of 
the MCP-1 message (Figure 4.15). 
 
To confirm that ET-1 was acting transcriptionally, we transiently transfected 
cells with wild-type MCP-1 promoter and enhancer luciferase reporter 
constructs.  ET-1 significantly increased MCP-1 promoter-luciferase reporter 
activity and there was a trend towards activation of the MCP-1 enhancer 
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construct (Figures 4.16 and 4.17 respectively), supporting the hypothesis that 
ET-1 regulates MCP-1 expression by HASMC transcriptionally.  There is one 
previous report of ET-1 increasing MCP-1 mRNA (in human brain-derived 
endothelial cells (241)) but, to our knowledge, this is the first study to show 
such an effect in HASMC and the first to demonstrate direct activation by ET-1 
of the MCP-1 promoter/enhancer  in any biological system.  The magnitude of 
ET-1’s effects on the MCP-1 promoter and enhancer constructs suggested that 
the promoter was more important in the transcriptional regulation of MCP-1 by 
ET-1.  We therefore focused our subsequent experiments on determining which 
transcription factors were most important in activation of the MCP-1 promoter 
by ET-1. 
 
There is little information on the transcription factors activated by ET-1.  In 
glioma cells, AP-1 is involved in ET-1-stimulated proenkephalin expression 
(347) and, in rat cardiac myocytes, ET-1-stimulated brain natriuretic peptide 
transcription involves NF-κB (348) and a ternary complex of GATA proteins 
and serum response factor-activated atrial natriuretic factor (349).  ET-1 has 
also been shown to increase Sp1 expression in rat cardiac myofibroblasts (350).  
However, there are no published studies on the transcription factors activated 
by ET-1 in HASMC.  The wild type MCP-1 enhancer region contains two NF-
κB binding sites; the MCP-1 promoter construct used in these studies includes 
two binding sites for AP-1, single Sp1, NF-κB and NF-1 binding sites and a 
CCAAT box (Figure 3.1).  Given that previous studies have implicated AP-1, 
NF-κB and Sp1 in ET-1-stimulated responses in other systems, any or all of 
these transcription factors could potentially be important in ET-1-induced 
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MCP-1 expression.  Using serially deleted MCP-1 promoter constructs, we 
found that a region between 213 and 128 base pairs upstream of the 
translational start site was both necessary and sufficient for maximal activation 
of the MCP-1 promoter by ET-1 (Figure 4.18).  This region harbours consensus 
sequences for the NF-κB and AP-1 transcription factors.  Truncation of the 
promoter to -213 bp disrupts the GAS found at -214 to -204 bp, therefore it is 
unlikely that the GAS is involved in ET-1’s effects, although it is possible that 
this region retains some functionality.  Site directed mutagenesis or additional 
deletion analysis of the GAS would be required to clarify this further. 
 
The magnitude of the effect of ET-1 on the MCP-1 promoter deletion 
constructs was modest, and smaller that that on the MCP-1 promoter construct 
(Figures 4.16 and 4.18 respectively).  The deletion series was a gift from 
another laboratory; the serially deleted promoters were cloned into the 
commercially supplied PGL2 basic plasmid (Promega).  In contrast, the wild-
type MCP-1 promoter used in this study was cloned into the newer PGL3 basic 
plasmid vector (Promega).  These plasmids have been sequentially optimised 
by the supplying company to improve, amongst other characteristics, reporter 
gene expression in response to stimulation of cloned regulatory elements.  This 
may in part explain the smaller effects of ET-1 seen with the deletion 
constructs.  Although a formal quantification of the efficiency of our 
transfection system (Fugene 6, Roche Molecular Biochemicals) was not 
specifically performed for this study, other researchers in the Knox lab have 
demonstrated an overall efficiency of transfection in HASMC of 10 – 15% 
when transfecting a green fluorescent protein-expressing plasmid using the 
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Fugene 6 system (K. Deacon, personal communication).  The relative 
advantages and disadvantages of this system are discussed in more detail in 
Chapter 6 (Methodological Considerations) 
 
Our studies with the NF-κB and AP-1 luciferase reporter constructs showed 
that ET-1 activated both of these transcription factors in HASM (Figures 4.19 
and 4.20 respectively).  This is consistent with a role for these transcription 
factors in transcriptional regulation of MCP-1 by ET-1.  Furthermore the 
results of ChIP assays (Figures 4.23 and 4.24) and of NF-κB pathway 
inhibition by TPCA-1  (Figure 4.22) (351) support a role for NF-κB and AP-1 
in ET-1-stimulated MCP-1 expression.  The MEK inhibitor PD98059 and the 
p38 MAPK inhibitor SB203580 inhibited binding of p65 and cJun to the MCP-
1 promoter, suggesting that these kinases mediate ET-1-stimulated MCP-1 
production transcriptionally, via NF-κB and AP-1 (Figure 4.25).  It was beyond 
the scope of this study to determine the precise mechanisms by which p38 and 
p44/42 MAPK alter p65 and cJun binding to the MCP-1 promoter.  However 
this could be brought about through phosphorylation of components of the NF-
κB and cJun activating pathways, or by affecting chromatin accessibility.  To 
our knowledge, this is the first study to delineate the kinase cascades used by 
ET-1 to activate specific transcription factors. 
 
The effect of ET-1 on NF-κB reporter luciferase activity was relatively small 
(1.7-fold increase).  Although the ChIP studies and the effect of NF-κB 
pathway inhibition on ET-1-stimulated MCP-1 expression provide additional 
evidence of a role for NF-κB, additional techniques could have been employed 
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to strengthen these findings.  These include studies of NF-κB nuclear 
translocation, through immunofluorescence studies or Western blotting of 
nuclear and cytosolic fractions before and after stimulation with ET-1, or 
studies of NF-κB phosphorylation or IκB degradation by Western blotting. 
 
We were surprised that the JNK inhibitor SP600125 had no effect on either 
MCP-1 protein release or promoter activation (Figures 4.12 and 4.21 
respectively), as JNK is an upstream activator of cJun and, taken together, our 
transfection and ChIP studies strongly suggest that cJun mediates 
transcriptional regulation of MCP-1 by ET-1.  However, there are reports of 
JNK-independent activation of cJun (352), including by p44/42 MAPK (353).  
Thus ET-1-mediated activation of cJun in HASMC may be occurring by a 
JNK-independent pathway. 
 
In the ChIP assays, binding of p65 and of cJun to the MCP-1 promoter was 
transient and relatively short lived, maximal at 1 hour in both cases, and 
returning to baseline by 1.5 hours in the case of p65, and by 2.5 hours for cJun.  
In contrast, an increase in MCP-1 mRNA was first seen at 2 hours, peaking 
later, at 8 hours.  A similar phenomenon was seen in the transcriptional 
regulation of eotaxin release by TNF-α, where p65 binding and histone 
acetylation at the eotaxin promoter was maximal at 30 - 60 min, waning by 2.5 
hrs, whereas eotaxin mRNA peaked later, at 4 hours, suggesting that the two 
processes are not temporally contiguous (224).  Similar responses have been 
observed in the Knox lab in the regulation of other chemokines by TNF-α and 
IL-1 (K Deacon, personal communication).  A possible explanation for this 
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observation is that, once transcriptional activation has taken place through 
transcription factor binding and chromatin remodelling at promoter regions, the 
transcriptional apparatus is free to continue transcribing the coding region of 
the gene, even after transcription factor dissociation from the promoter. 
 
The magnitude of ET-1’s effects on p65 and cJun binding to the MCP-1 
promoter, as measured by semi-quantitative PCR and densitometry, is modest.  
For the ChIP studies, we would ideally have liked to quantify the 
immunoprecipitated material by qPCR.  However, we encountered a number of 
technical difficulties in optimising the qPRC assay for the region of interest of 
the MCP-1 promoter.  This is discussed in more detail in chapter 6. 
 
Our transcriptional studies of ET-1-stimulated MCP-1 release (mRNA studies, 
reporter gene assays and ChIP assays) all showed relatively modest effects of 
ET-1 relative to the more pronounced effect on MCP-1 protein release.  This 
may be for a number of reasons.  First, as described above, transcriptional 
activation in vivo is in part regulated through chromatin remodelling and the 
epigenetic code.  In the reporter gene assays, the MCP-1 promoter and 
enhancer plasmid vectors lack the native chromatin environment of the 
chromosomal MCP-1 gene.  Thus transcriptional activation of the reporter gene 
vectors is likely to be less efficient in the absence of the normal chromatin 
structure.  Secondly, ET-1’s effects may be amplified between the mRNA level 
and the level of protein expression through signalling cascades.  Thirdly, other 
than mRNA stability studies, we did not explore any post-transcriptional 
mechanisms.  It may be that ET-1 exerts its effects on MCP-1 expression, in 
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part, through post-transcriptional mechanisms.  However, a detailed 
exploration of post-transcriptional mechanisms was beyond the scope of this 
study. 
 
There have been a number of studies of MCP-1 transcriptional regulation in the 
context of inflammation.  These have demonstrated involvement of various 
transcription factors in MCP-1 regulation in an apparently stimulus- and tissue-
specific manner.  For example, STAT-1 and Sp1 were found to interact with 
the MCP-1 promoter in response to interferon gamma (IFN-γ) in macrophages 
(354).  In contrast, in rat aorta cells hyperinsulinaemia induced C/EBP binding 
to the MCP-1 promoter (355).  Intriguingly, Teferedegne et al defined an 
ordered sequence of events in the TNF-α-regulated activation of the MCP-1 
promoter in a human fibroblast cell line (223).  TNF-α induced binding of NF-
κB to the MCP-1 enhancer, triggering recruitment of the transcriptional co-
activators and histone acetyltransferase enzymes CBP and p300.  This 
facilitated interaction of the distal MCP-1 enhancer with the proximal promoter 
region, enabling Sp1 binding to the promoter region and subsequent activation 
of transcription.  Whilst a number of studies have indirectly implied 
involvement of AP-1 in MCP-1 transcriptional regulation, for example through 
correlation of levels of MCP-1 expression with transcription factor expression 
or activation (356, 357), or through electrophoretic mobility shift assay studies 
(358, 359), to our knowledge this is the first study to directly demonstrate in 
vivo binding of AP-1 to the MCP-1 promoter by ChIP assay.  This is one of 
very few reports of MCP-1 regulation by mediators acting at GPCRs (360) and, 
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to our knowledge is the first to demonstrate in vivo binding of NF-κB and cJun 
to the MCP-1 promoter in response to ET-1 in any biological system. 
 
Inhibition of the NF-κB pathway has been shown to inhibit the release of other 
inflammatory cytokines and chemokines from HASMC and to inhibit cytokine 
expression and inflammatory cell accumulation in the lungs of a rodent model 
of asthma following ovalbumin challenge (361).  NF-κB pathway blockade 
also inhibited the late asthmatic response in the ovalbumin-challenged animals 
(361).  Our results with ET-1 add to the body of evidence suggesting that 
targeting common downstream signalling moieties, such as NF-κB, may have 
therapeutic potential by simultaneously inhibiting multiple inflammatory 
pathways.  
 
In conclusion, this study is the first to delineate the signalling pathways used 
by ET-1 to increase production of MCP-1, an important chemokine strongly 
implicated in asthmatic airway inflammation.  We have shown that ET-1 
regulates MCP-1 by transcriptional mechanisms involving NF-κB and AP-1, 
and that the upstream signalling pathways involve both ETA and ETB receptors 
and p38 and p44/p42 MAP kinases.  Our propsed mechanism of MCP-1 
regulation by ET-1 is summarised in Figure 4.26.  This study adds to the 
growing body of evidence implicating a number of common downstream 
targets, including MAP kinases and the pro-inflammatory transcription factor 
NF-κB, onto which multiple inflammatory signalling pathways converge.  
Such targets are likely to be relevant in the development of new therapeutic 
modalities for the treatment of asthma.
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Figure 4.26  Proposed sequence of events in the transcriptional regulation 
of MCP-1 by ET-1.  ET-1, acting at ETA and ETB receptors, activates p38 
and p44/42 MAP kinases.  Activation of these kinases leads on to 
activation of cJun and p65, the latter through activation of IKK-2, leading 
to phosphorylation and dissociation of I-κB, allowing translocation of p65 
from the cytosol to the nucleus.  Upon activation, cJun and p65 bind to the 
MCP-1 promoter, allowing RNA polymerase II to bind at the 
transcriptional start site and synthesise MCP-1 mRNA.  Multiple arrows 
indicate probable multiple steps in the signalling pathways that were not 
fully characterised in this study.  It is not clear whether the two ET 
receptors activate distinct kinase cascades, or whether both receptors can 
activate p38 and p44/42. 
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CHAPTER 5:  REGULATION OF EOTAXIN EXPRESSION BY TNF-α AND ITS 
MODULATION BY GLUCOCORTICOIDS AND LONG ACTING BETA AGONISTS:  
ROLE OF NF-κB, HISTONE H3 ACETYLATION AND HISTONE DEACETYLASES 
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5.1 Introduction 
Allergic airway inflammation in asthma is characterised by accumulation of 
eosinophils within local tissues.  Eotaxin is an important CC chemokine that is 
a potent chemoattractant for eosinophils and plays an important role in 
eosinophilic inflammation (362).  As described in Chapter 1, airway smooth 
muscle cells are critically involved in inflammation and remodelling in the 
asthmatic airway, and studies from this lab and others have previously shown 
that eotaxin is released from these cells in response to proinflammatory 
cytokines such as IL-1β and TNF-α (203, 363). 
 
The main two classes of drugs used in the treatment of asthma in the clinical 
setting are ICS and β2-adrenoceptor agonists (β2-agonists).  Clinical studies 
have shown that treatment of patients with moderate to severe asthma with a 
combination of ICS and LABA provides superior benefit compared to 
treatment with either class of drug alone (364, 365).  It is currently unclear 
whether the superiority of the LABA/ICS combination is due to their 
complementary mechanisms of action or due to additive or synergistic effects 
on airway inflammation.  The mechanisms of the anti-inflammatory effects of 
GC have been discussed in detail in chapter 1.  By contrast, the potential anti-
inflammatory effects of LABA are less well understood, but may involve 
effects on mast cell stabilisation, plasma exudation or inflammatory cell 
trafficking, independent of the actions of GC (366).  However, there is 
increasing interest in the interactions between LABA and GC, and a number of 
observations support the possibility of additive or synergistic effects of these 
agents on inflammatory gene expression.  For example, β2 agonists caused 
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nuclear translocation and DNA binding of the GR in a fibroblast cell line (367).   
Furthermore, salmeterol enhanced the ability of dexamethasone to suppress 
proliferation and cytokine release from allergen-stimulated human peripheral 
blood mononuclear cells (368).  Similar additive effects of LABA and GC on 
cytokine release were observed in cultured human airway epithelial cells (369) 
and, in fibroblasts, salmeterol also enhanced the suppressive effect of 
fluticasone on the expression of intercellular adhesion molecule-1 (370). 
 
In keeping with these clinical and laboratory observations, this group has 
shown previously that GC and β2-agonists both inhibit TNF-α-stimulated 
eotaxin and IL-8 release from HASMC and that, when used in combination, the 
two classes of drug have additive or synergistic effects (154, 203, 224).  This is 
interesting, as it may explain, in part, the clinical observations when these 
drugs are administered in combination.  We have begun to explore the 
mechanisms involved. 
 
Inflammatory gene expression is regulated at several levels. These include 
activation of transcription factors (such as NF-κB) via kinase cascades, binding 
of transcription factors to specific recognition elements in gene promoters, by 
chromatin remodelling, and through post-transcriptional modification.  As 
described in chapter 1, transcriptional regulation of genes in their native 
chromatin environment is highly complex, involving covalent modifications to 
histone proteins, resulting in a more open chromatin structure, and facilitating 
binding of transcription factors and their co-factors and activation of 
transcription.  Acetylation of histone proteins is brought about by HATs, and 
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deacetylation by HDACs.  Our previous studies showed that TNF-α increased 
eotaxin release through a transcriptional mechanism.  The effects of TNF-α at 
the eotaxin promoter were largely mediated by the transcription factor NF-κB, 
and the mechanism involved acetylation of histone H4 associated with the 
eotaxin promoter (224).  This same study went on to show that the GC, 
fluticasone propionate (FP) and the LABA salmeterol (salme) inhibited TNF-
α-induced p65 binding and histone H4 acetylation at the eotaxin promoter 
(224).  Again, the two drugs in combination had additive effects.  However, the 
mechanisms by which FP and salme repressed histone H4 acetylation, and 
thereby NF-κB recruitment to the eotaxin promoter remain unclear.  
Furthermore, it is not known whether TNF-α alters acetylation status of other 
histones at the eotaxin promoter, and whether, therefore, part of the effects of 
FP and salme may be mediated through effects on acetylation status of other 
histone proteins. 
 
Recently, there has been interest in the roles of HDACs in inflammatory 
airways diseases including asthma and COPD.  In studies of bronchial biopsies 
of patients with asthma, levels of HDACs 1 and 2 were reduced compared to 
control subjects, whereas HDAC 2 levels in asthmatic patients treated with ICS 
were the same as control subjects.  Furthermore, total HDAC activity in 
bronchial biopsies of patients with asthma was also reduced compared to 
control subjects, and was significantly higher (although still reduced compared 
to controls) in patients treated with ICS (371).  Similar observations were noted 
in alveolar macrophages isolated from asthmatic patients and normal controls 
(372).  Similarly, HDAC 2 expression and total HDAC activity was reduced in 
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peripheral lung tissue and alveolar macrophages of patients with COPD 
compared to normal controls (298).  The possibility that targeting HDACs may 
be of therapeutic potential has been raised by the observation that the existing 
PDE4 inhibitor, theophylline, used to treat COPD and asthma, increased 
HDAC activity in bronchial biopsies of patients with asthma, and that the 
increase in HDAC activity showed a positive correlation with PC20 for 
methacholine and correlated inversely with sputum eosinophilia (373).  There 
is also evidence that, in response to glucocorticoid stimulation, the GR can 
interact with HDACs to inhibit histone acetylation induced by inflammatory 
cytokines (220).  However, the mechanism through which TNF-α induced 
histone H4 acetylation at the eotaxin promoter is not fully understood, 
furthermore, the mechanisms used by FP and salme to reduce histone H4 
acetylation and p65 recruitment to the eotaxin promoter are not known.  In the 
experiments described in this chapter we sought to explore these mechanisms 
in more detail.  Using a variety of cellular and molecular assays, we tested the 
hypotheses that: 
 
1. TNF-α causes other histone acetylation events (namely H3 acetylation) 
at the eotaxin promoter. 
2. FP and salme modulate TNF-α-stimulated NF-κB activation. 
3. TNF-α, FP and salme alter the expression of the key anti-inflammatory 
HDACs 1 and 2 in HASMC. 
4. TNF-α, FP and salme alter total HDAC activity in HASMC. 
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5.2  Experimental protocols 
HASMC were grown in 6 well plates (Western blotting experiments, HDAC 
activity assay), 75cm2 flasks (ChIP assay) or 24 well plates (all other 
experiments) as described in chapter 3.  Cells were growth arrested for 24 h 
prior to each experiment.  The principle findings of these studies were 
confirmed in tissue from three different donors.  Subsequent mechanistic 
studies were performed on cells from one to three donors.   
 
5.2.1 Eotaxin release from HASMC 
Human eotaxin release from HASMC was measured using a commercially 
available ELISA kit (R&D) as described in chapter 3. 
 
5.2.2 Determination of HDAC 1 and 2 mRNA expression by real time 
polymerase chain reaction. 
Real time PCR was carried out as described in chapter 3.  Primer sequences 
used were:  HDAC-1 sense, 5’- ACC GGG CAA CGT TAC GAA T-3’; 
HDAC-1 antisense, 5’- CTA TCA AAG GAC ACG CCA AGT G -3’; HDAC-
2 sense, 5’- TCA TTG GAA AAT TGA CAG CAT AGT -3’; HDAC-2 
antisense, 5’- CAT GGT GAT GGT GTT GAA GAA G -3’; β2 microglubulin 
sense, 5’- GAG TAT GCC TGC CGT GTG-3’; β2 microglobulin antisense, 5’- 
AAT CCA AAT GCG GCA TCT-3’ (302). 
 
5.2.3 Nuclear extractions for total HDAC activity assay 
Nuclear extractions were performed using the NuCLEAR™ (Sigma) extraction 
kit according to the manufacturers protocol with some modifications.  HASMC 
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were grown to confluence in 90 mm Petri dishes.  One dish was used per 
condition.  Cells were washed twice in ice-cold PBS prior to transfer to 
microcentrifuge tubes and centrifugation at 450g for 5 min at 4°C.  The 
supernatants were discarded and the cells resuspended in hypotonic lysis buffer 
(supplied) supplemented with PIC and 1µM dithiothreitol (DTT) at a ratio of 
5µl lysis buffer : 1µl packed cell volume.  Samples were incubated on ice for 
15 min prior to addition of 10% Igepal (6 µl Igepal to 100 µl lysate).  The 
lysates were centrifuged at 10,000g for 30 sec at 4°C.  The supernatants 
containing the cytoplasmic fraction were removed and the pellet containing the 
nuclear fraction washed with lysis buffer.  The pellets were resuspended in 
extraction buffer (supplied) supplemented with PIC and 1 µM DTT (0.66 µl 
extraction buffer to 1 µl packed cell volume) and vortexed for 15 min.  The 
samples were then centrifuged at 20,000g for 5 min at 4°C and the supernatants 
containing the nuclear fractions snap frozen in liquid nitrogen prior to storage 
at -70°C until use. 
 
5.2.4 Histone deacetylase assay 
HDAC assay was performed using a colorimetric assay kit according to the 
manufacturer’s protocol (Upstate).  HASMC were treated with TNF-α (10 
ng/ml) for the times indicated.  In inhibitor studies, cells were pre-incubated 
with inhibitors or vehicle for 30 min prior to treatment with TNF-α (10 ng/ml).  
Following stimulation, nuclear extracts were prepared as described in section 
5.2.3.  Thirty µg of nuclear extract in a volume of 20 µl was added to 10µl of 2 
x HDAC assay buffer (supplied) in duplicate into wells of the supplied 96 well 
plate and allowed to equilibrate to 37°C.  Ten µl of 4 mM HDAC assay 
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substrate (supplied) was added to each well, the plate mixed and incubated at 
37°C for 60 min to allow deacetylation of the colorimetric substrate by HDAC 
enzymes contained in the test samples.  To release the colorimetric molecule 
from the deacetylated substrate, 20 µl of activator solution containing 4 µM 
trichostatin A (TSA) was added to each well.  The plate was mixed and 
incubated at room temperature for 20 min prior to reading absorbance at 405 
nm in a microplate reader (Tecan GENios).  A standard curve was generated by 
serial two-fold dilution of the provided 1 mM HDAC assay standard.  The 
standards were incubated with the test samples and treated identically from 
addition of activator solution.  Twenty µl of HeLa nuclear extract (supplied), or 
20 µl of HeLa nuclear extract plus TSA were assayed alongside the test 
samples as positive and negative controls respectively.  Results were expressed 
as absorbance at 450 nm A450 (arbitrary units).  Effects of drugs (FP, salme) 
were expressed as percentages of control values. 
 
5.2.5 Chromatin immunoprecipitation assay 
ChIP assay was performed as described in chapter 3.  Primer sequences used to 
amplify the immunoprecipitated products by PCR were as follows:  eotaxin 
promoter sense: 5’-CTT CAT GTT GGA GGC TGA AG-3’; eotaxin promoter 
antisense: 5’-GGA TCT GGA ATC TGG TCA GC-3’. 
 
5.2.6 Data analysis 
Results were expressed as the means of the individual technical replicates for 
that experiment.  The experiments were repeated at least twice, and the results 
shown represent group means +/- SE.  Absolute eotaxin levels are presented for 
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the initial concentration response and inhibitor experiments.  In subsequent 
mechanistic studies, the data are expressed as fold increase or percentage of 
control.  The number of independent experiments from which the data are 
derived is also indicated in the figure legends.  Analysis of variance (ANOVA) 
of the raw data was used to determine statistically significant differences.  A p 
value of <0.05 was regarded as statistically significant. 
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5.3 Results 
5.3.1 TNF-α stimulates the release of eotaxin from cultured HASMC 
We first studied the effect of TNF-α on eotaxin release from HASMC.  
HASMC were stimulated for 24 h with 0 – 100 ng/ml TNF-α.  TNF-α 
concentration-dependently stimulated eotaxin release from HASMC (Figure 
5.1). 
 
 
 
Figure 5.1. Effect of TNF-α on eotaxin release from HASMC.  HASMC 
were incubated for 24 h with TNF-α at the concentrations indicated.  
TNF-α caused a concentration-dependent increase in eotaxin release from 
HASMC (p<0.001).  Each bar represents group mean (SE) derived from 8 
replicates in 3 independent experiments performed on cells from 3 
different primary donors. 
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5.3.2  Fluticasone and salmeterol inhibit TNF-α-stimulated eotaxin release 
We next studied the effect of the glucocorticoid fluticasone propionate (FP) 
and the long-acting beta agonist salmeterol (salme) on TNF-α-stimulated 
eotaxin release.  Both FP (10-7 and 10-6 M) and salme (10-7 and 10-6 M) 
inhibited TNF-α-stimulated eotaxin release (Figure 5.2). 
 
 
 
 
Figure 5.2. Fluticasone (FP, 10-7 and 10-6 M) and salmeterol (Salme, 10-7 
and 10-6 M) significantly inhibited eotaxin release from cells stimulated 
with TNF-α (10 ng/ml).  ## p < 0.01 compared with unstimulated (control) 
cells. * p< 0.05, ** p < 0.01 compared with TNF-α-stimulated cells.  Each 
bar represents group mean (SE) derived from 9 replicates in 3 
independent experiments. 
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5.3.3  TNF-α does not cause acetylation of histone H3 associated with the 
eotaxin promoter 
Previous work the Knox group has shown that TNF-α increases histone H4 
acetylation and thence p65 recruitment to the eotaxin promoter and that FP and 
salme downregulate H4 acetylation and p65 binding.  The mechanisms by 
which FP and salme reduce p65 binding are not clear.  We initially sought to 
determine, by ChIP, whether other histones, namely histone H3 associated with 
the eotaxin promoter were acetylated in response to TNF-α.  However, we 
found that TNF-α had no effect on H3 acetylation at the eotaxin promoter 
(Figure 5.3).  Since the lack of upregulation of histone H3 acetylation makes it 
unlikely that FP and salme were exerting their effects on p65 binding through 
effects on H3 acetylation, we did not explore this further. 
 
 
 
Figure 5.3.  ChIP assay, with accompanying densitometry, showing effect 
of TNF-α on histone H3 acetylation at the eotaxin promoter.  HASMC 
were treated with TNF-α (10 ng/ml) for the times indicated.  The density 
of the immunoprecipitated band (IP) was normalised to that of the input 
control at the same time point, and expressed as fold increase over time 
zero.  Representative gel from one of two independent experiments.  
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5.3.4  TNF-α stimulates NF-κB reporter activity in HASMC: fluticasone and 
salmeterol do not alter this response 
Since our previous studies showed that FP and salme down-regulated TNF-α-
induced NF-κB p65 binding to the eotaxin promoter, we went on to study the 
effect of TNF-α, FP and salme on a transiently transfected NF-κB reporter 
construct.  TNF-α (10 ng/ml, 6 h) concentration-dependently stimulated NF-
κB reporter activity in HASMC (Figure 5.4).  However, FP and salme had no 
effect on TNF-α-stimulated NF-κB reporter activity (Figures 5.5 and 5.6), 
suggesting that the effect of these drugs on p65 binding to the eotaxin promoter 
is not through altering NF-κB activation. 
 
 
Figure 5.4. Concentration response of TNF-α-stimulated NF-κB 
reporter activity.  HASMC were transiently transfected with an NF-κB 
reporter construct and stimulated with TNF-α for 6 h at the 
concentrations indicated.  TNF-α concentration-dependently stimulated 
NF-κB reporter activity (p<0.001).  Each bar represents group mean (SE) 
derived from 12 determinates in 3 independent experiments. 
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Figure 5.5. Fluticasone had no effect on TNF-α-stimulated NF-κB 
reporter activity when cells were stimulated with a sub-maximal 
concentration of TNF-α (1 ng/ml).  Each bar represents group mean (SE) 
derived from 20 determinates in 5 independent experiments.  *** p < 0.001 
compared to unstimulated (control) cells.  Overall p for effect of 
fluticasone = 0.425. 
 
Figure 5.6. Salmeterol had no effect on TNF-α-stimulated NF-κB 
reporter activity when cells were stimulated with a sub-maximal 
concentration of TNF-α (1 ng/ml).   Each bar represents group mean (SE) 
derived from 12 determinates in 3 independent experiments.  *** p < 0.001 
compared to unstimulated (control) cells.  Overall p for effect of 
salmeterol = 0.269. 
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5.3.5  TNF-α does not affect HDAC 1 and 2 mRNA levels 
Alterations in histone acetylation and transcription factor recruitment may be 
brought about by altered global HDAC or HAT activity, altered HDAC or 
HAT expression, or altered recruitment of specific HATs or HDACs to the 
gene promoter.  We therefore went on to study the effect of TNF-α (10 ng/ml) 
on total HDAC 1 and 2 mRNA levels.  We quantified HDAC 1 and 2 mRNA 
levels by qRT-PCR.  HDAC mRNA levels were normalised to the 
housekeeping gene β2-microglobulin (β2M).  We found that there was a decay 
of HDAC 1 and 2 mRNA levels over the 24 h studied, but there was no 
significant difference between control (unstimulated) and TNF-α-stimulated 
cells (Figures 5.7 and 5.8 respectively). 
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Figure 5.7. Effect of TNF-α (10 ng/ml) on HDAC 1 mRNA levels.  There 
was a time-dependent decay in HDAC 1 mRNA levels but no differences 
were observed between control and TNF-α-stimulated cells (p=0.15).  
Each bar represents mean (SE) derived from 4 independent experiments. 
 
 
 
 
Figure 5.8. Effect of TNF-α (10 ng/ml) on HDAC 2 mRNA levels.  There 
was a time-dependent decay in HDAC 2 mRNA levels but no differences 
were observed between control and TNF-α-stimulated cells (p=0.76).  
Each bar represents mean (SE) derived from 4 independent experiments. 
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5.3.6  TNF-α does not affect HDAC 1 and 2 protein levels 
As there were no differences in HDAC 1 and 2 mRNA levels between control 
and TNF-α-stimulated cells, we speculated that TNF-α may alter levels of 
HDAC expression at the protein level.  HDAC 1 and 2 protein levels were 
therefore studied by Western blot of whole cell lysates (Figures 5.9 and 5.10 
respectively).  There was no change in HDAC 1 and 2 protein levels in 
response to TNF-α stimulation over the time course studied. 
 
 
 
Figure 5.9. TNF-α (10 ng/ml) had no effect on total HDAC 1 protein 
levels by Western blotting.  Representative blots from one of two 
independent experiments. 
 
 
 
 
Figure 5.10. TNF-α (10 ng/ml) had no effect on total HDAC 2 protein 
levels by Western blotting.  Representative blots from one of two 
independent experiments. 
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5.3.7  Fluticasone and salmeterol do not affect HDAC 1 and 2 protein levels 
Since our group’s previous studies have shown that FP and salme 
downregulate TNF-α-stimulated H4 acetylation and p65 recruitment to the 
eotaxin promoter (224), but our NF-κB reporter gene assays suggested that this 
was not due to an effect on TNF-α stimulated NF-κB activation (Figures 5.5 
and 5.6), we hypothesised that FP and salme’s effects may be mediated through 
altered levels of HDAC expression.  We were most interested in their effects 
under TNF-α-stimulated conditions, since the aim of these experiments was to 
determine the mechanism by which these drugs altered TNF-α-stimulated H4 
acetylation and p65 recruitment to the exotaxin promoter.  However, since 
TNF-α itself did not affect levels of HDAC 1 and 2 expression, we also tested 
the effects of FP and salme on unstimulated cells.  We found that FP and salme 
at 1µM had no effect on HDAC 1 and 2 levels in either unstimulated or TNF-
α-stimulated cells (Figures 5.11 to 5.14). 
 134 
 
 
Figure 5.11. Fluticasone (1 µM) had no effect on total HDAC 1 protein 
levels in either unstimulated or TNF-α-stimulated cells.  Representative 
blots from one of two independent experiments. 
 
 
 
 
Figure 5.12. Fluticasone (1 µM) had no effect on total HDAC 2 protein 
levels in either unstimulated or TNF-α-stimulated cells.  Representative 
blots from one of two independent experiments. 
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Figure 5.13. Salmeterol (1 µM) had no effect on total HDAC 1 protein 
levels in either unstimulated or TNF-α-stimulated cells.  Representative 
blots from one of two independent experiments. 
 
 
 
 
Figure 5.14. Salmeterol (1 µM) had no effect on total HDAC 2 protein 
levels in either unstimulated or TNF-α stimulated cells.  Representative 
blots from one of two independent experiments. 
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5.3.8  TNF-α does not alter total HDAC activity 
Since TNF-α had no effect on levels of HDAC 1 and 2 at either the mRNA or 
protein level, we hypothesised that TNF-α might increase HDAC activity 
without modifying mRNA/protein levels. To test this hypothesis we measured 
HDAC activity using a commercially available assay.  HASMC were incubated 
with TNF-α (10 ng/ml) for the times indicated.  TNF-α had no effect on total 
HDAC activity over the time course studied (Figure 5.15). 
 
 
 
 
Figure 5.15 Effect of TNF-α on global HDAC activity in HASMC.  
HASMC were stimulated with TNF-α (10 ng/ml) for the times indicated.  
Nuclear extracts were assayed for total HDAC activity, measured by 
colorimetric assay as absorbance at 450 nm (A450).  TNF-α had no effect 
on total HDAC activity in HASMC.  Each bar represents mean (SE) 
derived from 4 independent experiments. 
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5.3.9  Fluticasone and salmeterol do not affect total HDAC activity 
Similarly, since FP and salme had no effect on levels of HDAC protein 
expression, we speculated that these drugs may alter total HDAC activity.  
However, FP and salme had no effect on total HDAC activity in either 
unstimulated or TNF-α-stimulated conditions at 4 and 24 h (Figures 5.16 and 
5.17). 
 
 
 
 
Figure 5.16  Effect of salmeterol (1 µM) and fluticasone (1µM) on total 
HDAC activity in unstimulated HASMC.  Cells were incubated for 4 or 24 
h in the presence of salmeterol or fluticasone.  Salmeterol and fluticasone 
had no effect on total HDAC activity. Each bar represents mean (SE) 
derived from 2 independent experiments. 
Co
ntr
ol Mµ
Sa
lm
ete
ro
l 1
 
Mµ
Flu
tic
as
on
e 
1 
0
50
100
150
200
4hrs
24hrs
To
ta
l H
D
AC
 
ac
tiv
ity
(%
 
o
f c
o
n
tr
o
l)
 
 138 
 
 
 
 
 
 
Figure 5.17  Effect of salmeterol (1 µM) and fluticasone (1µM) on total 
HDAC activity in TNF-α stimulated HASMC.  Cells were pre-incubated 
for 30 min with vehicle, salmeterol or fluticasone then stimulated for 4 or 
24 h with TNF-α (10 ng/ml).  Salmeterol and fluticasone had no effect on 
total HDAC activity.  Each bar represents mean (SE) derived from 2 
independent experiments. 
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5.4  Discussion 
The human eotaxin promoter has been cloned and a number of putative 
regulatory elements identified, including binding sites for C/EBP, AP-1, NF-
κB and STAT-6 (374-376).  Eotaxin gene regulation is predominantly 
mediated by NF-κB and STAT-6, in a tissue- and stimulus-specific manner.  In 
human airway epithelial cells, NF-κB mediates TNF-α-induced transcription, 
whereas IL-4-stimulated transcription is mediated by STAT-6.  Neither 
stimulus promoted binding of C/EBP or AP-1 to eotaxin promoter elements 
(376).  In contrast, in fibroblasts, TNF-α-induced eotaxin transcription is 
mediated by both NF-κB and STAT-6 (377).  In previous studies from this 
group, the mechanism of TNF-α-induced eotaxin expression was explored in 
more detail in HASMC.  We found that TNF-α regulated eotaxin expression 
transcriptionally and, furthermore, TNF-α’s effects were predominantly 
mediated by NF-κB.  TNF-α promoted binding of NF-κB p65 to the eotaxin 
promoter and acetylation of histone H4 associated with the eotaxin promoter 
(224). 
 
We have previously shown that TNF-α-stimulated eotaxin release from 
HASMC is modulated by FP and salme (203).  Subsequent studies showed that 
TNF-α regulates eotaxin transcriptionally and that FP and salme inhibit TNF-
α-induced eotaxin transactivation.  Furthermore, in vivo ChIP studies showed 
that FP and salme repressed TNF-α-stimulated eotaxin transcription through 
inhibition of histone H4 acetylation and p65 binding at the eotaxin promoter 
(224).  In this study we set out to determine the mechanisms by which FP and 
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salme might modulate histone acetylation events and NF-κB-dependent 
activation of the eotaxin promoter. 
 
We first confirmed the original observations by our group that TNF-α 
concentration-dependently stimulated eotaxin release from HASMC (Figure 
5.1) and that FP and salme significantly inhibited TNF-α-stimulated eotaxin 
release (Figure 5.2). The results of these experiments were broadly in 
agreement with the previous reports from our group (203, 224).   
 
We initially turned our attention to histone acetylation events, exploring 
whether TNF-α affected acetylation of other histone proteins, specifically 
histone H3, at the eotaxin promoter, by ChIP assay.  Although the role of 
histone H4 acetylation has been studied quite extensively in inflammatory gene 
regulation (183, 220, 224, 250, 378), histone H3 modifications in association 
with inflammatory gene promoters are less well studied, although have been 
described (379-381).  We found that TNF-α (10 ng/ml) had no effect on 
histone H3 acetylation (Figure 5.3).  This makes it unlikely that histone H3 
acetylation events contribute to FP and salme effects on TNF-α-stimulated p65 
recruitment to the eotaxin promoter.  We therefore did not pursue this line of 
enquiry further. 
 
The previous study by Nie et al showed that FP and salme inhibited in vivo 
NF-κB p65 binding to the eotaxin promoter.  We therefore went on to 
determine if the effects of salme and FP were through NF-κB activation.  To 
do this we transiently transfected HASMC with an NF-κB luciferase reporter 
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construct.  The advantage of this approach is that it is a relatively 
straightforward assay system which can give useful information on 
transcription factors or genes activated or downregulated in response to a 
particular stimulus.  A potential disadvantage is that the transfected vectors 
lack the chromatin environment of native DNA, so results need to be 
interpreted with caution, since the lack of a chromatin environment may alter 
some responses.  We found that TNF-α concentration-dependently stimulated 
the activity of a transiently transfected NF-κB reporter construct (Figure 5.4).  
Interestingly, however, FP and salme had no effect on TNF-α-stimulated NF-
κB reporter activity (Figures 5.5 and 5.6 respectively).  As described in chapter 
1, the binding of transcription factors and their co-factors to gene promoters, 
and activation of transcription, involves covalent modifications to histone 
proteins, promoting a more open chromatin structure.  We know from previous 
studies in our laboratory that FP and salme inhibition of binding of NF-κB to 
the eotaxin promoter was dependent on the chromatin environment and 
associated with acetylation of histone H4.  It was not seen when EMSA assays 
were used which lack this chromatin environment (224).  The results with the 
NF-κB reporter assay are probably compatible with this lack of effect of FP 
and salme, reflecting the lack of a chromatin environment when reporter assays 
are used.   The observation that neither FP nor salme had any effect on TNF-α-
stimulated NF-κB reporter activity suggests that their effects are not mediated 
through direct inhibition of NF-κB or its upstream activating pathway, but that 
some other, perhaps chromatin-dependent mechanism is involved. 
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We speculated that the effects of TNF-α on NF-κB binding and histone H4 
acetylation at the eotaxin promoter may be mediated through an effect on 
histone deacetylase (HDAC) levels.  Since HDACs act to remove acetyl groups 
from acetylated histone proteins, a down-regulation of HDACs might be 
expected to increase total acetylation at the eotaxin promoter.  Further, since 
transcription factor binding is facilitated by histone acetylation, 
downregulation of HDACs could also explain the increase in NF-κB binding to 
the eotaxin promoter in response to TNF-α.  The aforementioned studies on 
bronchial biopsies of patients with asthma (371, 372), would support the 
hypothesis that alterations in the amounts of HDACs 1 and 2 may be important 
in promoting inflammatory gene expression in asthma.  We therefore studied 
the effect of TNF-α (10 ng/ml) on total HDAC mRNA and protein levels, 
focusing our studies on HDAC 1 and 2.  We found that there was a decay of 
HDAC 1 and 2 mRNA levels over the 24 h studied, but there was no difference 
between control (unstimulated) and TNF-α-stimulated cells (Figures 5.7 and 
5.8).  HDAC 1 and 2 protein levels were studied by Western blotting (Figures 
5.9 and 5.10 respectively).  HDACs 1 and 2 belong to the class I HDACs, 
which are exclusively localised to the nucleus and do not shuttle between 
nucleus and cytoplasm (382).  For this reason we studied their levels in whole 
cell lysates rather than nuclear and cytoplasmic fractions.  There was no 
change in HDAC 1 and 2 protein levels in response to TNF-α stimulation over 
the time course studied, suggesting that alterations in levels of HDAC 
expression are not responsible for the effects of TNF-α on NF-κB binding and 
histone acetylation at the eotaxin promoter. 
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Although TNF-α had no effect on HDAC 1 and 2 levels, we hypothesised that 
FP and/or salme may upregulate total HDAC 1 and 2 levels, which may 
explain the effects of these drugs on H4 acetylation and NF-κB binding at the 
eotaxin promoter.  As our experiments with TNF-α alone had shown no effect 
on HDAC 1 and 2 levels,  but any effect of FP or salme would be most relevant 
in TNF-α stimulated cells (since we were interested in effects on the eotaxin 
promoter under stimulated conditions), we performed the experiments in both 
unstimulated and TNF-α-stimulated cells.  We found that FP and salme at 
1µM, concentrations that this group has previously shown reduce acetylation of 
H4 and NF-κB binding at the eotaxin promoter (224), had no effect on HDAC 
1 and 2 levels in either unstimulated or TNF-α-stimulated cells (Figures 5.11 to 
5.14). 
 
In some of the Western blots depicting HDAC1 levels under various conditions 
and at various time points, a second, slightly lower molecular weight band was 
observed.  This band was also noted in the other experiments of which the data 
presented are representative.  This second band did not have a consistent 
relationship to time, presence or absence of TNF-α or presence or absence of 
fluticasone.  It most likely represents a non-specific band with a similar 
molecular weight to HDAC-1.  To our knowledge, HDAC1 is not expressed as 
splice variants.  An alternative explanation may be post-transcriptional 
modification of HDAC-1, which is subject to various of these, including 
phosphorylation, acetylation, sumoylation and ubiquitylation (383).  SUMO 
(small ubiquitin-like modifier) proteins consist of around 100 amino acids, 
with a molecular weight of approximately 12kDa.  Ubiquitin consists of around 
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76 amino acids, with a molecular weight of around 8.5 kDa.  Such 
modifications would therefore alter the molecular weight of HDAC1 by an 
amount consistent with the additional band observed in some, but not all of the 
HDAC1 Western blots.  However, these post translational modifications are 
tightly regulated, having important effects on cellular functions.  Thus it is 
difficult to reconcile this possibility with the inconsistent relationship of the 
additional band with the various conditions and time points studied, and non-
specific binding remains a more likely explanation. 
 
Despite the lack of effect of TNF-α, FP and salme on HDAC 1 and 2 mRNA or 
protein levels, it is possible that their effects on histone H4 acetylation and NF-
κB binding to the eotaxin promoter may be mediated through alterations of 
HDAC activity, particularly as the previously described studies in bronchial 
biopsies and alveolar macrophages from asthmatic patients showed reduced 
HDAC activity in these  patients compared to normal controls (371, 372).  We 
therefore studied the effects of TNF-α, FP and salme on total HDAC activity in 
HASMC.  TNF-α had no effect on HDAC activity in HASMC (Figure 5.15).  
This contrasts with the findings of Keslacy et al, who found an increase in total 
HDAC activity in HASMC stimulated with TNF-α (384).  We are unsure why 
this should be the case, since the conditions for preparation, culture and 
treatment of HASMC used in our laboratory were very similar to those 
described by Keslacy et al.  Similarly, FP and salme had no effect on HDAC 
activity in either unstimulated or TNF-α-stimulated conditions (Figures 5.16 
and 5.17). 
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In summary, taken together, these data suggest that the mechanisms by which 
TNF-α, FP and salme bring about their effects on histone H4 acetylation at the 
eotaxin promoter is not through alterations in HDAC levels or activity.  
Furthermore, since TNF-α had no effect on histone H3 acetlylation at the 
eotaxin promoter, it is unlikely that alterations in histone H3 acetylation 
contribute to FP and salme’s effects on p65 recruitment to the eotaxin 
promoter.  This begs the question, what other mechanisms may be responsible 
for the effects of FP and salme? 
 
We focused our studies on HDACs 1 and 2 as these have been shown to have 
altered levels in inflammatory lung diseases (298, 371).  However, it is 
possible that alterations in levels of other HDACs may have been responsible.  
An alternative explanation is that FP and salme either inhibit recruitment of 
essential HATs to the eotaxin promoter, or promote recruitment of 
counterregulatory HDACs.  A recently published study by this group 
demonstrated that TNF-α increased p300 and pCAF recruitment to the eotaxin 
promoter (228).  It would be interesting to extend these studies to determine 
whether FP or salme modulate TNF-α-stimulated p300 or PCAF recruitment.  
Similarly, ChIP assays could be employed to study the association of HDACs 
with the eotaxin promoter, and whether their association is up- or 
downregulated by TNF-α/FP/salme.  There is certainly evidence from co-
immunoprecipitation studies in A549 transformed alveolar epithelial cells that 
another GC, dexamethasone, in association with the GR, can recruit HDAC 2 
to the activated p65/CBP complex.  This observation was associated with an 
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inhibition of IL-1β-induced histone acetylation at the granulocyte-macrophage 
colony stimulating factor promoter (220). 
 
Salme is a LABA that acts at β-adrenergic receptors at the cell surface to 
increase intracellular levels of cAMP.  Cyclic AMP activates cAMP-responsive 
genes through binding of cAMP response element binding protein (CREB) to 
the cAMP response element (CRE).  It is possible that the effects of salme are 
mediated indirectly through induction of cAMP-responsive genes.  It is 
tempting here to draw parallels with the effects of theophylline on HDAC 
activity since theophylline inhibits PDE4, thus resulting in elevated 
intracellular cAMP levels.  However, the study by Ito et al found the effects of 
theophylline to be independent of PDE4 inhibition (373). 
 
In addition to acetylation of histones, it is now known that other cellular 
proteins may be targets for both HATs and HDACs.  These include 
transcription factors such as NF-κB (385), the GR (299) and molecular 
chaperone proteins critical to normal GR function (386).  It would be 
interesting to determine whether FP or salme alter acetylation status of these 
other regulatory elements in HASMC, and whether this has any bearing on 
regulation of inflammatory response genes such as eotaxin. 
 
In conclusion, we have shown that FP and salme do not inhibit TNF-α induced 
histone H4 acetylation or p65 binding at the eotaxin promoter through 
alterations in H3 acetylation status, alterations in levels of HDAC 1 and 2 
expression, or changes in total HDAC activity.  Other possible mechanisms 
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include effects on HAT or HDAC binding to the eotaxin promoter, changes in 
expression of HDACs other than 1 or 2, or perhaps alterations in acetylation 
status of other important nuclear regulators. 
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CHAPTER 6:  METHODOLOGICAL CONSIDERATIONS 
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6.1  Introduction 
Several methodological considerations relating to the studies presented in this 
thesis are worthy of mention.  These are discussed below. 
 
6.2  Transcriptional regulation 
In these studies, we explored transcriptional regulation using real time PCR, 
assays of transiently transfected reporter genes, and ChIP assays. 
 
6.2.1  Polymerase chain reaction 
In chapter 4, in our studies of endothelin receptor expression, we were 
interested solely in whether HASMC expressed the mRNA for the endothelin 
receptors, ETA and ETB.  We therefore used semi-quantitative RT-PCR to 
demonstrate the presence of ETAR and ETBR mRNA.  In contrast, in our 
studies of MCP-1 mRNA expression, we wanted to quantify MCP-1 mRNA 
levels to determine any changes in expression in response to ET-1.  We 
therefore used quantitative real time reverse transcriptase PCR (qRT-PCR) to 
measure MCP-1 mRNA.  With this technique, amplified DNA is quantified as 
it accumulates in the reaction in real time after each amplification cycle, either 
through quantification of fluorescent dyes, such as SYBR Green, that 
intercalate with double-stranded DNA (as used in this study), or fluorescent 
probes that hybridise to a specific DNA target sequence. This allows for more 
accurate quantification of transcripts than the semi-quantitative RT-PCR.  
Potential pitfalls of dye-based qRT-PCR include non-specific amplification and 
primer dimer formation, particularly at very low target concentrations.  In these 
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studies, dissociation curve analysis was undertaken and no secondary peaks 
suggestive of primer dimer formation or non-specific products were observed. 
 
6.2.2  Transient transfections 
We used FuGene 6 transfection reagent for all transfections.  FuGene 6 is a 
proprietary blend of lipids and other components supplied in 80% ethanol that 
is said to transfect eukaryotic cells with high efficiency and minimal 
cytotoxicity (387).  We found that this method produced acceptable levels of 
transfection of plasmid DNA into HASMC, as reflected in detectable levels of 
luciferase activity, consistently above background levels.  A formal 
quantification of transfection efficiency was not performed.  Other methods of 
transfection include the use of liposomal transfection reagents, such as 
Lipofectamine (Invitrogen), or the use of nucleofection systems such as that 
produced by Amaxa.  Liposomal reagents probably have similar efficacy to 
Fugene 6.  Indeed, in published studies from this lab we have found similar 
levels of efficacy using Lipofectamine to transfect HASMC (184).  We have 
some experience in our laboratory of using the Amaxa nucleofection system.  
This method combines electroporation with a cell-type specific Nucleofector 
solution, and is useful for those applications that require very high transfection 
efficiencies, for example gene knock-down protocols utilising small interfering 
RNA.  However, we observed higher levels of cytotoxicity using this method 
than with standard transfection reagents (LM Corbett, unpublished 
observations).  Furthermore, the Amaxa system is prohibitively expensive for 
applications such as reporter gene assays, where such high transfection 
efficiencies are not essential. 
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Reporter gene assays such as those used in this study place a gene with a 
readily measurable product (in this case, firefly luciferase) under the control of 
the promoter (or other regulatory sequence) of the target gene of interest.  
Following transfection of the cells with the reporter plasmid, cells are treated 
with stimuli and/or drugs/inhibitors of interest.  The level of luciferase 
expression provides a measure of the effect of the treatment on activity of the 
gene promoter and, by extrapolation, expression of the target gene.  Reporter 
gene assays are a relatively simple, convenient means of studying gene 
regulation.  However, this technique assumes that the process of transfection 
does not alter the response of the cells to the treatment under study.  
Furthermore, eukaryotic DNA in its native form exists as chromatin, a complex 
structure consisting of DNA wound around 4 core histones (H2A, H2B, H3, 
H4).  These histones undergo a number of covalent modifications 
(acetylation/phosphorylation/methylation) which regulate chromatin unwinding 
thereby allowing access of transcription factors to their binding sites on DNA, 
recruitment of essential co-factors and activation of transcription.  Since 
eukaryotic genes are normally regulated, in part, through this “epigenetic” 
code, and since reporter plasmids lack this chromatin structure, reporter gene 
assays can only give a partial insight into gene regulation events in vivo. 
 
6.2.3  Chromatin immunoprecipitation assay 
In contrast to reporter gene assays, ChIP assays study gene regulation events 
“in vivo” (in this context, in vivo refers to DNA in its native environment in the 
form of chromatin).  Following treatment with the stimulus under study, DNA 
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is covalently cross linked to bound proteins (transcription factors, histones, 
essential cofactors) through a fixing procedure.  After shearing the DNA into 
approximately 500bp fragments, DNA bound to the transcription factor (or 
other protein) of interest is immunoprecipitated with an antibody directed 
against the relevant protein.  After reversal of the cross links, the target region 
of interest is amplified by PCR using specific primers spanning the regulatory 
region of the gene under study.  Thus if a stimulus triggers binding of a 
particular transcription factor to the gene promoter, then the amount of PCR 
product will be increased.  ChIP assays are therefore more physiological than 
some other techniques used to study gene regulation, such as reporter gene 
assays and electrophoretic mobility shift assays. 
 
We used ChIP assays in the studies presented in chapters 4 and 5, to study 
transcription factor binding to the MCP-1 promoter, and to study histone H3 
acetylation at the eotaxin promoter in response to TNF-α.  Disadvantages of 
ChIP include the need for large amounts of starting material (two 75cm2 flasks 
of cells per condition in this study) and the number of steps involved in the 
procedure, which may potentially lead to some loss of sample and therefore 
some inter-sample variability. 
 
In chapter 4, the magnitude of ET-1’s effects on p65 and cJun binding to the 
MCP-1 promoter, as measured by semi-quantitative PCR and densitometry, is 
modest.  For the ChIP studies, we would ideally have liked to quantify the 
immunoprecipitated material by qPCR.  However, we encountered a number of 
technical difficulties in optimising the qPRC assay for the region of interest of 
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the MCP-1 promoter.  In ChIP, the quantity of DNA immunoprecipitated is 
small, thus the amount of starting material for the PCR assay is lower than in 
some other PCR applications.  Although it is important that the reaction 
efficiency should be as high as practicably possible for all qPCR applications, a 
high reaction efficiency and specificity is even more critical where the quantity 
of starting material is very small.  This requires the design of effective primers, 
however, ChIP and qPCR both place certain constraints on primer design.  
First, for qPCR applications it is best to aim for as short an amplicon as 
possible (max 200 bp) to ensure efficient denaturation during thermal cycling.  
Second, in studies of transcription factor binding by ChIP, the region of interest 
is in the gene promoter, and must span the binding sites for the transcription 
factors under study.  Together, these two constraints limit the region of DNA to 
which one can design primers to hybridize. Ideally the resulting amplicon 
should have a GC content of less than 60%, again to ensure efficient 
denaturation during thermal cycling, yet promoter regions are often GC rich.  
Within these constraints, using freely available on-line primer design tools 
(CyberGene), we found that most possible primer pairs that could potentially 
amplify the region of interest of the MCP-1 promoter had potential for 
secondary structure (hairpin loop) formation.  Despite this, we tested a number 
of primer pairs, against a standard curve generated through serial dilutions of 
human genomic DNA (hgDNA) but the resulting qPCR reaction was not 
sufficiently efficient for accurate quantification of immunoprecipitated 
products. 
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We therefore used semi-quantitative PCR to analyse our ChIP data.  For each 
sample, an aliquot of DNA was removed as an input control, prior to addition 
of antibody (immunoprecipitation step), thus acting as a control for any 
variability in the total DNA recovered from each sample.  Results were then 
quantified by densitometry of the immunoprecipitated bands, normalised to the 
corresponding input and compared with time zero (time course experiments) or 
untreated samples.  To confirm that the PCR product generated in the ChIP 
studies was indeed from the MCP-1 promoter, the band was excised and 
sequenced.  The sequence products aligned with the MCP-1 promoter, with no 
other hits by NCBI BLAST for the whole human genome, confirming that the 
PCR product was from the MCP-1 promoter. 
 
Another technique that could have been employed to support the ChIP data is 
EMSA (electrophoretic mobility shift assay), however this technique suffers 
from the limitation that transcription factors are binding to synthetic 
oligonucleotides, not to native DNA in the form of chromatin.  Thus EMSA is 
a less physiological assay than ChIP, meaning that results must be interpreted 
with caution. 
 
6.3  Receptor studies 
In our studies of ET-1-stimulated MCP-1 release in chapter 4, the combination 
of the presence of mRNA for both ET receptors, and inhibition of ET-1 
mediated responses by both ETA and ETB receptor antagonists, provides strong 
evidence of the presence and involvement of both receptor subtypes.  To 
provide further evidence of the presence of both receptors at the protein level, 
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antibody detection strategies, such as flow cytometry or immunofluoresecence 
studies could be employed.  Although the ETA and ETB receptor antagonists 
were used at concentrations that should be selective for their respective targets 
(324, 325), to rule out non-selective effects and provide further evidence of the 
involvement of both receptors, molecular approaches such as knock down of 
receptor expression with siRNA could have been employed. 
 
6.4  Kinase studies 
There are conflicting reports in the literature regarding the selectivity of the 
kinase inhibitors SB203580, PD98059 and SP600125 for their targets.  Whilst 
the concentrations of inhibitors used have previously been reported to be 
selective for these pathways (328-331), subsequent studies have suggested that 
these inhibitors may have non-selective effects in some systems (388).  
However, we have previously found, in TNF-α-stimulated HASMC, that 
SB203580 (30 µM) does not inhibit phosphorylation of p44/p42 MAPK and, 
similarly, PD98059 (30 µM) does not inhibit phosphorylation of p38 MAPK, 
suggesting that these inhibitors are selective for their respective targets in these 
cells (Clarke DL and Knox AJ, unpublished observations). 
 
Other methods that could have been used to confirm the involvement of these 
kinases in this pathway include knock-down of kinase effects using, for 
example, siRNA, or dominant negative studies in which cells are transfected 
with a vector encoding a non-functional variant of the relevant kinase thereby 
knocking out the kinase function (389). 
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No experimental system is 100% physiological, and all have their 
shortcomings.  The studies presented in this thesis were performed with the 
methodological considerations discussed above in mind.  For this reason, we 
have used a range of techniques in our mechanistic studies (eg transient 
transfections as well as ChIP assays for studies of transcriptional regulation).  
Consequently, the conclusions drawn from those studies and presented here 
are, we feel, valid and strongly supported by the data presented. 
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CHAPTER 7:  CONCLUSIONS AND SUGGESTIONS FOR FUTURE STUDIES 
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7.1  Conclusions 
The purpose of these studies was to explore the mechanisms of inflammatory 
response gene regulation in HASMC by mediators and cytokines important in 
asthmatic airway inflammation.  Specifically, we aimed to identify common 
pathways onto which multiple inflammatory pathways converge, that may be 
targets for future drug development for asthma.  We studied ET-1 and TNF-α 
as examples of an important inflammatory mediator and cytokine respectively, 
and focused on regulation of chemokine expression, using the two important 
chemokines MCP-1 and eotaxin as examples. 
 
We chose primary HASMC for our studies.  These cells secrete a variety of 
biologically active substances important in asthmatic airway inflammation and 
remodelling.  They express receptors for cytokines such as TNF-α and IL-1β, 
as well as G-protein coupled receptors for many inflammatory mediators (178).  
They are thus a useful model system to study regulation of these pathways and, 
as primary cells, are more physiologically representative than transformed cell 
lines. 
 
The main findings of these studies were that ET-1 regulates MCP-1 release 
from HASMC transcriptionally, by activating the MCP-1 promoter through 
binding of the pro-inflammatory transcription factors NF-κB and AP-1.  ET-
1’s effects were mediated via ETA and ETB receptors, and the downstream 
signalling pathway involved p38 and p44/p42 MAP kinases.  Similarly, the 
effects of TNF-α on eotaxin expression were also NF-κB-dependent.  NF-κB-
dependent eotaxin expression in response to TNF-α has been previously shown 
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to involve histone H4 acetylation at the eotaxin promoter (224).  In these 
studies, we found that TNF-α-mediated eotaxin release did not involve 
acetylation of histone H3 at the eotaxin promoter, and that alterations in the 
levels of HDACs 1 and 2, or of total HDAC activity, did not account for TNF-
α effects on H4 acetylation.  Further, that although FP and salme downregulate 
H4 acetylation and NF-κB p65 binding, this also was not mediated by changes 
in HDAC levels or activity. 
 
These findings are novel, in that although there are isolated reports of ET-1 
increasing MCP-1 production in endothelial and mesangial cells (241, 334), the 
mechanisms used by ET-1 to up-regulate MCP-1 expression have not been 
studied in any biological system.  This is also one of very few studies that have 
demonstrated in vivo binding of transcription factors to inflammatory gene 
promoters in response to GPCR-activating mediators.  Similarly, the 
mechanisms regulating modulation of NF-κB binding and histone acetylation 
in response to TNF-α at the eotaxin promoter have not been previously 
investigated. 
 
The findings of these studies have implications for understanding the 
pathophysiology of asthma.  There is an emerging body of evidence that the 
myriad of intracellular signalling events triggered by inflammatory mediators 
and cytokines may converge on a small number of downstream pathways that 
are key to the inflammatory response.  These potential “key players” include 
the MAP kinase pathways (390) and the NF-κB-activating pathway (277).  
ET-1 is found in elevated levels in the asthmatic airway and, as discussed in 
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chapter 1, plays a significant role in airway inflammation and 
bronchoconstriction in asthma.  However, it is generally accepted that the vast 
numbers of cytokines and mediators at play in the asthmatic airway leads to a 
complex network of overlapping inflammatory responses; this explains why 
single mediator approaches to treating asthma (using drugs targeting, for 
example, histamine or leukotriene-mediated pathways) have limited efficacy.  
This has stimulated the research effort aimed at identifying the “key players” 
referred to above.  We showed that ET-1 stimulates MCP-1 release via p38 and 
p44/p42 MAPK, enzymes known to also mediate a number of cytokine-driven 
responses (217).  Such findings suggest that targeting MAP kinases may be of 
benefit in the management of inflammatory diseases such as asthma.  There is 
evidence from animal models that such a strategy may be beneficial (391). 
 
Like TNF-α-mediated eotaxin release, we found that NF-κB was involved in 
the transcriptional regulation of MCP-1 by ET-1.  AP-1 was also involved in 
this response.  This is interesting, as it adds to the body of evidence showing 
that these two particular transcription factors are key regulators of multiple 
inflammatory responses (277, 278).  The NF-κB pathway in particular has been 
the subject of intense study, and inhibition of this pathway has been shown to 
reduce inflammation and the late asthmatic response in animal models (361).   
 
Although we did not explore potential synergistic effects in these studies, the 
fact that TNF-α and ET-1 can both activate common pathways such as the 
MAP kinases and NF-κB suggests that they may be able to synergise to further 
increase inflammatory responses, when present together in the complex 
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inflammatory milieu of the asthmatic airway.  This further supports the concept 
that targeting these common pathways may be beneficial in treating human 
disease. 
 
Recently, there has been increasing interest in the role in inflammatory gene 
regulation of chromatin remodelling and the regulatory proteins that bring this 
about.  Histone acetylation has received the most attention in this context.  
Cytokines are known to promote histone acetylation at the promoters of a 
number of inflammatory response genes, including acetylation of histone H4 at 
the eotaxin promoter by TNF-α (183, 220, 224).  In these studies, we have 
explored this mechanism in more detail, finding that levels of HDAC1 and 2 
expression and global HDAC activity were not the responsible mechanisms.  
Furthermore, alterations in HDAC expression/activity were not responsible for 
the effects of FP and salme on TNF-α-stimulated eotaxin expression.  These 
studies suggest that targeting HDACs therapeutically may not be the most 
effective anti-inflammatory strategy, although it would be important to explore 
whether HDACs are key to regulating other inflammatory response genes 
before discounting them as potential therapeutic targets. 
 
In conclusion, we have delineated the signalling pathway used by ET-1 to 
increase MCP-1 expression in HASMC.  We have found that this pathway 
shares some common features with cytokine-mediated signalling, in particular 
that of TNF-α.  We have extended earlier studies to characterise the 
mechanisms by which TNF-α, GC and LABA modulate transcriptional 
regulation at the eotaxin promoter, and shown that HDACs do not mediate 
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these events.  These studies are likely to be of relevance to the understanding 
and treatment of asthmatic airway inflammation. 
 
7.2  Suggestions for future studies 
As discussed in chapter 1, nuclear signalling by mediators acting at GPCRs is 
less well characterised than cytokine-mediated signalling.  Our studies with 
ET-1 therefore focused on intracellular signalling cascades, promoter 
activation and binding of transcription factors to the MCP-1 promoter.  It 
would be interesting to extend these studies in the future to determine whether 
activation of transcription at the MCP-1 promoter by ET-1 involves HAT-
mediated chromatin remodelling events similar to those seen with TNF-α (222-
224).  HATs and HDACs have been proposed as exciting new targets for future 
asthma treatments (382), and further characterising their roles in inflammatory 
gene regulation will be important in clarifying which of these are the key 
regulatory proteins in asthmatic airway inflammation. 
 
In contrast to GPCR-mediated signalling, studies of nuclear signalling by 
cytokines are at a more advanced stage.  Our studies with TNF-α therefore 
focused more on chromatin remodelling events.  Although we showed that 
global HDAC activity and total HDAC1 and 2 levels were not responsible for 
the effects of TNF-α, FP and salme at the eotaxin promoter, it is possible that 
alterations in HDAC recruitment to the eotaxin promoter and thence changes in 
promoter acetylation status may be responsible.  ChIP assays could be used to 
explore this possibility. 
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In our studies of MCP-1 regulation by ET-1, we used inhibitor studies to show 
that MAP kinases were involved in the signalling pathway.  Although we have 
data from our lab to show that these inhibitors are selective, at the 
concentrations used, for their respective targets in HASMC (Clarke DL and 
Knox AJ, unpublished observations), it would strengthen our observations to 
confirm these findings using molecular strategies such as siRNA or dominant 
negative kinases.  It would also be of interest to delineate the signalling 
cascades in more detail.  Our studies suggested that ET-1 activates AP-1 by a 
JNK-independent mechanism in these cells.  This is a recognised (352, 353), 
but not commonly reported phenomenon, and it would be interesting to know 
exactly which upstream kinases were responsible.  It would also be appealing 
to determine whether, like TNF-α-mediated events, steroids and LABA can 
alter the expression of MCP-1 in response to ET-1, and to explore the 
mechanisms involved. 
 
Finally, our studies were performed in HASMC derived from non-asthmatic 
donors.  As discussed in section 1.4.6, a number of functional differences have 
been identified between cells derived from normal and asthmatic donors.  The 
phenomena described in this thesis are worthy of study in asthmatic cells.  It is 
possible that there are significant differences that may be of pathophysiological 
relevance.  Comparative studies in asthmatic cells would give the most 
accurate assessment of the relevance of the effects we describe here. 
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APPENDIX:  CELL VIABILITY STUDIES 
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The effect on cell viability of the stimulants and inhibitors used in these studies 
was assessed by MTT assay.  In all of the following figures, MTT assay was 
performed after 24 h treatment with stimulants/inhibitors.  Optical densities 
were read at 550 nm in a microplate reader.  Viability was compared to that of 
control cells, with viability of controls defined as 100%.  Cell viability with all 
chemicals/inhibitors used in this study was greater than 90% of that of control 
cells as shown in the following figures. 
 
 
 
 
Figure A.1  Effect of Bosentan on HASMC viability 
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Figure A.2  Effect of BQ123 and BQ788 on HASMC viability 
 
 
Figure A.3  Effect of SB203580, PD98059 and Wortmannin on HASMC 
viability 
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Figure A.4  Effect of SP600125 on HASMC viability 
 
 
 
Figure A.5  Effect of LY294002 on HASMC viability 
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Figure A.6  Effect of ET-1 (10 ng/ml), Act D (5µg/ml) and ET-1 and Act D 
in combination on HASMC viability 
 
 
 
Figure A.7  Effect of TPCA-1 on HASMC viability 
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